<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" id="c343481242" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Omega</journal-id><journal-id journal-id-type="iso-abbrev">ACS Omega</journal-id><journal-id journal-id-type="pmc-domain-id">3686</journal-id><journal-id journal-id-type="pmc-domain">acsomega</journal-id><journal-id journal-id-type="publisher-id">ao</journal-id><journal-title-group><journal-title>ACS Omega</journal-title></journal-title-group><issn pub-type="epub">2470-1343</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://pubs.acs.org/journal/acsodf">http://pubs.acs.org/journal/acsodf</self-uri></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12223813</article-id><article-id pub-id-type="pmcid-ver">PMC12223813.1</article-id><article-id pub-id-type="pmcaid">12223813</article-id><article-id pub-id-type="pmcaiid">12223813</article-id><article-id pub-id-type="pmid">40621026</article-id><article-id pub-id-type="doi">10.1021/acsomega.5c02998</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Antiproliferative
and Trypanocidal Activity of Ivermectin
Bioconjugates</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e22-autogenerated"><contrib id="ath1" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7343175</contrib-id><name name-style="western"><surname>Sulik</surname><given-names initials="M">Micha&#322;</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7577504</contrib-id><name name-style="western"><surname>Otto-&#346;lusarczyk</surname><given-names initials="D">Dagmara</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">913626</contrib-id><name name-style="western"><surname>Steverding</surname><given-names initials="D">Dietmar</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath4" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1095529</contrib-id><name name-style="western"><surname>Struga</surname><given-names initials="M">Marta</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath5" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1047379</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4770-215X</contrib-id><name name-style="western"><surname>Huczy&#324;ski</surname><given-names initials="A">Adam</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/></contrib><aff id="aff1">
<label>&#8224;</label>
<institution content-type="dept">Department
of Medical Chemistry, Faculty of Chemistry</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">49562</institution-id><institution>Adam Mickiewicz University</institution></institution-wrap>, <addr-line>Uniwersytetu Pozna&#324;skiego 8</addr-line>, <postal-code>61&#8722;614</postal-code>
<city>Pozna&#324;</city>, <country country="PL">Poland</country>
</aff><aff id="aff2">
<label>&#8225;</label>
<institution content-type="dept">Chair
and Department of Biochemistry, Faculty of Medicine</institution>, <institution>Medical University of Warsaw</institution>, <addr-line>Banacha 1</addr-line>, <postal-code>02&#8722;097</postal-code>
<city>Warsaw</city>, <country country="PL">Poland</country>
</aff><aff id="aff3">
<label>&#167;</label>
<institution content-type="dept">Bob
Champion Research &amp; Education Building, Norwich Medical School</institution>, <institution>University of East Anglia</institution>, <city>Norwich</city>
<postal-code>NR4 7TJ</postal-code>, <country country="GB">U.K.</country>
</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>adhucz@amu.edu.pl</email>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>18</day><month>6</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>01</day><month>7</month><year>2025</year></pub-date><volume>10</volume><issue>25</issue><issue-id pub-id-type="pmc-issue-id">492158</issue-id><fpage>27380</fpage><lpage>27392</lpage><history><date date-type="received"><day>02</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>06</day><month>6</month><year>2025</year></date><date date-type="rev-recd"><day>29</day><month>5</month><year>2025</year></date><date date-type="online"><day>18</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-07 09:25:16.833"><day>07</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read content-type="AuthorChoicev2" start_date="2025-06-18"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-06-18">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ao5c02998.pdf"/><abstract><p>Ivermectin (<bold>IVR</bold>), whose discovery has been
Nobel-Prize-honored,
is a 16-membered macrocyclic lactone used in medicine as an extremely
effective and safe antiparasitic drug. In recent years, interest in
this compound has grown due to its potential effectiveness in killing
various types of cancer cells. However, research on the anticancer
activity of <bold>IVR</bold> derivatives is limited. Additionally,
the growing problem of drug resistance raises concerns about the effectiveness
of this drug in the treatment of parasitic diseases. Therefore, in
this work, we provide a detailed description of the synthesis of ten
new <bold>IVR</bold> bioconjugates with compounds exhibiting high
anticancer and/or antimicrobial activity. We also assess the effectiveness
of these hybrids in killing a protozoan parasite that causes African trypanosomiasis, as well
as their anticancer activity toward various cancer cell lines. Many
of the newly synthesized conjugates exhibited higher biological activity
than their respective parent compounds as well as increased selectivity
indices. The <bold>IVR</bold> conjugate with artesunate (compound <bold>16</bold>) appears particularly interesting, as it proved not only
to be several times more active than the parent compounds but also
showed no toxicity toward a reference cell line, indicating its potential
as a therapeutic agent.</p></abstract><abstract abstract-type="graphical"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="abs1" position="float" orientation="portrait" xlink:href="ao5c02998_0009.jpg"/></abstract><abstract abstract-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="tgr1" specific-use="not-for-print" position="float" orientation="portrait" xlink:href="ao5c02998_0007.jpg"/></abstract><funding-group><award-group id="fnd-1"><funding-source><institution-wrap><institution>Fundacja Uniwersytetu im. Adama Mickiewicza</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/100016906</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><funding-group><award-group id="fnd-2"><funding-source><institution-wrap><institution>Ministerstwo Edukacji i Nauki</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100004569</institution-id></institution-wrap></funding-source><award-id>0159/DIA/2020/49</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>ao5c02998</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>ao5c02998</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>d3007e6abc52cea76ff4b35e182ca85a68401648de76e00f1a3474999a630926</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p>Cancer is a global health
issue that continues to be one of the
leading causes of death in modern civilization. According to the World
Health Organization (WHO), in 2020, approximately 10 million people
died from cancer, while more than 19 million new cancer cases were
diagnosed worldwide.<named-content content-type="bibref-group">
<xref rid="ref1" ref-type="bibr"/>,<xref rid="ref2" ref-type="bibr"/>
</named-content> Despite significant progress in
modern therapeutic methods and numerous clinical studies currently
conducted across the world, the search for new candidates for effective
and safe anticancer drugs remains one of the most important challenges
of modern science and medicine.<named-content content-type="bibref-group">
<xref rid="ref1" ref-type="bibr"/>,<xref rid="ref2" ref-type="bibr"/>
</named-content> Among the anticancer
drugs currently in use, many classes of chemical compounds can be
distinguished, each characterized by a different mechanism of biological
activity. These include DNA-alkylating agents, mitosis inhibitors,
and antimetabolites.<xref rid="ref3" ref-type="bibr"/> Many of them&#8211;in
addition to their high anticancer activity&#8211;are also highly
toxic, which is often associated with the occurrence of serious side
effects.<xref rid="ref3" ref-type="bibr"/> One method of mitigating the
unfavorable toxicity of anticancer drugs is their bioconjugation with
other highly selective chemical compounds.<named-content content-type="bibref-group">
<xref rid="ref4" ref-type="bibr"/>,<xref rid="ref5" ref-type="bibr"/>
</named-content> Moreover,
if these compounds also exhibit anticancer activity, the resulting
hybrids may prove to be extremely effective in the fight against cancer,
as multiple cytotoxic mechanisms will act on the cell simultaneously.</p><p>Ivermectin (<bold>IVR</bold>, 1, <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>) is a 16-membered lactone isolated in 1967
from a strain.<xref rid="ref6" ref-type="bibr"/> This compound exhibits a broad spectrum of antiparasitic
activity and is used in the treatment of various parasitoses, such
as onchocerciasis, lymphatic filariasis, and scabies.<named-content content-type="bibref-group">
<xref rid="ref7" ref-type="bibr"/>,<xref rid="ref8" ref-type="bibr"/>
</named-content> It is used as a mixture of two homologues: B1a, which has an ethyl
group at position C26, and B1b, which has a methyl group at this position.<named-content content-type="bibref-group">
<xref rid="ref6" ref-type="bibr"/>,<xref rid="ref9" ref-type="bibr"/>
</named-content> The mixture consists of at least 80% B1a and no more than 20% of
B1b.<named-content content-type="bibref-group">
<xref rid="ref6" ref-type="bibr"/>,<xref rid="ref9" ref-type="bibr"/>
</named-content> Due to its potent antiparasitic activity
and safety profile, <bold>IVR</bold> is often referred to as a &#8220;wonder
drug&#8221;.<named-content content-type="bibref-group">
<xref rid="ref6" ref-type="bibr"/>,<xref rid="ref8" ref-type="bibr"/>,<xref rid="ref10" ref-type="bibr"/>
</named-content> Its
discovery was honored with the Nobel Prize in Physiology or Medicine
in 2015.<xref rid="ref11" ref-type="bibr"/> Recent studies have shown that,
besides its great potential in combating different parasites, this
drug exhibits high anticancer activity against various types of cancer
cell lines, including glioma, leukemia, pancreatic cancer, and colon
cancer.<xref rid="ref12" ref-type="bibr"/> The anticancer mechanism of action
of <bold>IVR</bold> is much more complex and involves many different
biochemical processes, including the inhibition of the synthesis of
multidrug resistance (MDR) proteins or the increase in reactive oxygen
species (ROS) levels.<named-content content-type="bibref-group">
<xref rid="ref12" ref-type="bibr"/>,<xref rid="ref13" ref-type="bibr"/>
</named-content> However, the data regarding the
anticancer activity of <bold>IVR</bold> derivatives remain limited
to only one publication, demonstrating that chemical modification
at position C13 can lead to analogs with increased antiproliferative
activity and/or improved selectivity.<xref rid="ref14" ref-type="bibr"/> In addition to these findings, <bold>IVR</bold> is a safe compound
with virtually no side effects and, therefore, is an extremely interesting
candidate for bioconjugation.</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>1</label><caption><p>Chemical structure of ivermectin (<bold>IVR</bold>), its C13-hybrid
with a chloroquine analog, and the C13-hybrid of <bold>IVR</bold> and
artesunate studied in this work.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr1" position="float" orientation="portrait" xlink:href="ao5c02998_0001.jpg"/></fig><p>The process of bioconjugation involves the linking
of two or more
bioactive molecules through covalent bonding.<named-content content-type="bibref-group">
<xref rid="ref4" ref-type="bibr"/>,<xref rid="ref5" ref-type="bibr"/>
</named-content> It
is one of the most often used strategies in developing new hybrids
with higher efficacy compared with that of the parent compounds. Bioconjugates
can be created by combining two or more biomolecules in a single molecule
or by linking biomolecules with synthetic small molecules.<named-content content-type="bibref-group">
<xref rid="ref4" ref-type="bibr"/>,<xref rid="ref5" ref-type="bibr"/>
</named-content> This technique was used for the chemical modification of <bold>IVR</bold> by synthesizing dual-acting hybrids with different conjugation partners,
such as aminoquinolines (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>) or ferrocene derivatives.<named-content content-type="bibref-group">
<xref rid="ref15" ref-type="bibr"/>,<xref rid="ref16" ref-type="bibr"/>
</named-content> These compounds showed high in vitro activity against the blood-stage
and liver-stage of parasites,
confirming their potential in combating malaria.<named-content content-type="bibref-group">
<xref rid="ref15" ref-type="bibr"/>,<xref rid="ref16" ref-type="bibr"/>
</named-content> Linkers with diverse structures and stabilities, such as carbonates,
urethanes, or the 1,2,3-triazole ring formed through copper&#173;(I)-catalyzed
alkyne&#8211;azide cycloaddition (CuAAC) between two conjugation
partners, were employed in the synthesis of the respective hybrids.<named-content content-type="bibref-group">
<xref rid="ref15" ref-type="bibr"/>,<xref rid="ref16" ref-type="bibr"/>
</named-content>
</p><p>Inspired by the results regarding the anticancer properties
of
C13 derivatives of <bold>IVR</bold> and the antimalarial properties
of hybrids of this drug, we decided to combine both research directions.
Herein, we present synthetic access to a series of ten <bold>IVR</bold> bioconjugates with other biologically active components, combined
using appropriate linkers (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>). Compounds exhibiting diverse biological activities
were selected as conjugation partners. These included cinchona bark
alkaloids (<bold>quinine</bold>, <bold>quinidine</bold>, <bold>cinchonine</bold>, and <bold>cinchonidine</bold>), which have been used for many years
as antimalarial and antiarrhythmic drugs, but their effectiveness
in overcoming drug resistance in cancer cells has also been documented.<named-content content-type="bibref-group">
<xref rid="ref17" ref-type="bibr"/>,<xref rid="ref18" ref-type="bibr"/>
</named-content> In addition to these compounds, we also chose two nucleoside analogs
(<bold>floxuridine</bold> and <bold>azidothymidine</bold>), which
are used as anticancer drugs but are characterized by high toxicity.<named-content content-type="bibref-group">
<xref rid="ref19" ref-type="bibr"/>,<xref rid="ref20" ref-type="bibr"/>
</named-content> Furthermore, we also included in the study <italic toggle="yes">N</italic>
<bold>-deacetylthiocolchicine</bold>, <bold>betulinic acid</bold>, <bold>artesunate</bold>, and <bold>metronidazole</bold>, known for their
potent biological activities (antimicrobial and/or anticancer).<named-content content-type="bibref-group">
<xref rid="ref21" ref-type="bibr"/>&#8722;<xref rid="ref22" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref23" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref24" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref25" ref-type="bibr"/>
</named-content>
</p><p>All newly synthesized conjugates were evaluated in vitro for
their
cytotoxic activity toward different cell lines. However, it should
be mentioned that the primary use of <bold>IVR</bold> is as an extremely
effective drug to treat various parasitic diseases.<xref rid="ref8" ref-type="bibr"/> Moreover, many of the conjugation partners named above
are also highly effective against parasites. Thus, the resulting hybrids
may exhibit potent antiparasitic activities, as well. To test the
antiparasitic properties of the bioconjugates, we selected , the causative agent of African
trypanosomiasis, a parasite belonging to the group of organisms causing
neglected tropical diseases.<named-content content-type="bibref-group">
<xref rid="ref26" ref-type="bibr"/>&#8722;<xref rid="ref27" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref28" ref-type="bibr"/>
</named-content> It should also be noted that
C13 derivatives of <bold>IVR</bold> display promising activity against .<xref rid="ref29" ref-type="bibr"/> Thanks to
preventive and new therapeutic interventions introduced by the World
Health Organization (WHO), the number of human African trypanosomiasis
(sleeping sickness) cases has been significantly reduced in recent
years, while animal African trypanosomiasis (nagana disease) remains
a problem in sub-Saharan Africa.<named-content content-type="bibref-group">
<xref rid="ref28" ref-type="bibr"/>,<xref rid="ref30" ref-type="bibr"/>
</named-content> However, due
to the limited number of drugs and the emergence of drug-resistant
parasites, the search for new bioactive compounds to combat this disease
is necessary.<xref rid="ref31" ref-type="bibr"/> Therefore, all newly synthesized
hybrids were also tested for their in vitro activity against bloodstream
forms of .</p></sec><sec id="sec2"><label>2</label><title>Results and Discussion</title><sec id="sec2.1"><label>2.1</label><title>Analogs Design and Synthesis</title><p>A characteristic
feature of <bold>IVR</bold> is the presence of a disaccharide moiety
at the C13 position. It has been shown that its presence is not necessary
for the antiparasitic activity of the drug, but the aglycone exhibits
generally poorer biological properties than the unmodified <bold>IVR</bold>.<named-content content-type="bibref-group">
<xref rid="ref32" ref-type="bibr"/>,<xref rid="ref33" ref-type="bibr"/>
</named-content> An interesting direction for research is,
therefore, the replacement of the sugar moiety with other chemical
groups. Thus, the synthesis of C13-hybrids of <bold>IVR</bold> with
compounds showing anticancer and/or antimicrobial activity was conducted.
Linkers with diverse chemical properties were used, including carbonates,
urethane, and 1,2,3-triazole rings. The reactions involved conjugation
partners in their unmodified form or after structural modifications.
In general, three methods of bioconjugate synthesis were employed.</p><p>The first method involved the use of triphosgene, enabling the
conjugation of <bold>IVR</bold> with cinchona bark alkaloids and <italic toggle="yes">N</italic>-deacetylthiocolchicine. The cinchona bark alkaloids were
used in their native form, while <italic toggle="yes">N</italic>-deacetylthiocolchicine
had to be synthesized. It has been shown that the substitution of
colchicine&#8217;s C10-methoxy group with a thiomethyl group increases
the molecular stability of the resulting thiocolchicine.<xref rid="ref21" ref-type="bibr"/> As further reaction required the presence of
a free amine group, a deacetylation of thiocolchicine was carried
out, resulting in <italic toggle="yes">N</italic>-deacetylthiocolchicine, which
was then used for subsequent bioconjugation (<xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>).<xref rid="ref21" ref-type="bibr"/>
</p><fig position="float" id="sch1" fig-type="scheme" orientation="portrait"><label>1</label><caption><title>Synthesis
of <italic toggle="yes">N</italic>-Deacetylthiocolchicine</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr2" position="float" orientation="portrait" xlink:href="ao5c02998_0002.jpg"/></fig><p>The bioconjugation reaction was carried out
between the appropriate
partners and the C5-protected aglycone of <bold>IVR</bold> (compound <bold>3</bold>, <xref rid="sch2" ref-type="fig">Scheme <xref rid="sch2" ref-type="fig"/>
</xref>). Compound <bold>3</bold> was obtained through a two-step reaction,
which included the solvolysis of the sugar moiety in the presence
of sulfuric acid and the protection of the C5-hydroxyl group using <italic toggle="yes">tert</italic>-butyldimethylsilyl chloride (<xref rid="sch2" ref-type="fig">Scheme <xref rid="sch2" ref-type="fig"/>
</xref>). The reaction between the C13-hydroxyl
group of compound <bold>3</bold> and the hydroxyl group of cinchona
bark alkaloids, or the amine group of <italic toggle="yes">N</italic>-deacetylthiocolchicine,
took place in the presence of triphosgene, which enabled the synthesis
of either a carbonate or urethane linker. Deprotection of position
C5 using <italic toggle="yes">p</italic>-toluenesulfonic acid allowed the formation
of hybrids <bold>4&#8211;8</bold> with overall yields from two steps
(bioconjugation and deprotection) ranging from 14 to 21% (<xref rid="sch2" ref-type="fig">Scheme <xref rid="sch2" ref-type="fig"/>
</xref>).</p><fig position="float" id="sch2" fig-type="scheme" orientation="portrait"><label>2</label><caption><title>Synthesis of Bioconjugates
of <bold>IVR</bold> with Cinchona Bark
Alkaloids and <italic toggle="yes">N</italic>-Deacetylthiocolchicine</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr3" position="float" orientation="portrait" xlink:href="ao5c02998_0003.jpg"/></fig><p>The second method allowed the conjugation of
the <bold>IVR</bold> skeleton with nucleoside analogs (floxuridine
and azidothymidine)
and metronidazole. Similarly to the first method, the linker was a
carbonate group; however, the use of triphosgene proved unsuitable
for these compounds, as no formation of the expected product was observed.
Therefore, we decided to use carbonyldiimidazole (CDI) as a conjugative
agent, which was proposed by Singh et al. in 2022 for the synthesis
of <bold>IVR</bold> conjugates with aminoquinolines (<xref rid="sch3" ref-type="fig">Scheme <xref rid="sch3" ref-type="fig"/>
</xref>).<xref rid="ref16" ref-type="bibr"/> For this purpose, C5-protected compound <bold>3</bold> was subjected
to a reaction with CDI, which allowed the synthesis of precursor <bold>9</bold>. This reagent was then added to a mixture of nucleoside
analogue or metronidazole with DBU. The reaction was conducted at
90 &#176;C, and the isolation and subsequent deprotection of the C5-hydroxyl
group resulted in the desired hybrids <bold>10&#8211;12</bold>, with
yields ranging from 15 to 30% (<xref rid="sch3" ref-type="fig">Scheme <xref rid="sch3" ref-type="fig"/>
</xref>).</p><fig position="float" id="sch3" fig-type="scheme" orientation="portrait"><label>3</label><caption><title>Synthesis of Bioconjugates of <bold>IVR</bold> with
Nucleoside Analogs
(Floxuridine and Azidothymidine) and Metronidazole</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr4" position="float" orientation="portrait" xlink:href="ao5c02998_0004.jpg"/></fig><p>The third method allowed the conjugation of <bold>IVR</bold> with
betulinic acid and artesunate through the use of the CuAAC reaction
under Meldal conditions (copper&#173;(I) iodide as the source of Cu&#173;(I) ions).<xref rid="ref34" ref-type="bibr"/> To facilitate this, it was necessary to prepare
the azide and propargyl partners to enable the click reaction. Propargyl
ester of betulinic acid was obtained by reacting betulinic acid with
propargyl bromide in the presence of DBU. However, these conditions
were unsuitable for the synthesis of the propargyl ester of artesunate,
as they led to the decomposition of the starting material. Consequently,
to obtain the ester, propargyl alcohol was used in the presence of
DCC and DMAP (<xref rid="sch4" ref-type="fig">Scheme <xref rid="sch4" ref-type="fig"/>
</xref>).</p><fig position="float" id="sch4" fig-type="scheme" orientation="portrait"><label>4</label><caption><title>Synthesis of Propargyl Esters of Betulinic Acid and Artesunate</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr5" position="float" orientation="portrait" xlink:href="ao5c02998_0005.jpg"/></fig><p>To prepare the C13-azide precursor of <bold>IVR</bold>, the procedure
described by Singh et al. was employed.<xref rid="ref15" ref-type="bibr"/> It involved the synthesis of a chloroacetyl ester <bold>13</bold> formed by the reaction between compound <bold>3</bold> and chloroacetyl
chloride (<xref rid="sch5" ref-type="fig">Scheme <xref rid="sch5" ref-type="fig"/>
</xref>).
This ester was then subjected to a nucleophilic substitution reaction
with sodium azide (<xref rid="sch5" ref-type="fig">Scheme <xref rid="sch5" ref-type="fig"/>
</xref>). The reaction did not proceed quantitatively, and the resulting
azide <bold>14</bold> was difficult to separate chromatographically.
Therefore, the click reaction was carried out using a mixture of azide <bold>14</bold> and substrate <bold>13</bold>.</p><fig position="float" id="sch5" fig-type="scheme" orientation="portrait"><label>5</label><caption><title>Synthesis of Bioconjugates
of <bold>IVR</bold> with Betulinic Acid
and Artesunate</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr6" position="float" orientation="portrait" xlink:href="ao5c02998_0006.jpg"/></fig><p>The obtained precursors (azide <bold>14</bold> and the respective
ester) were dissolved in acetonitrile, and then DIPEA and copper&#173;(I)
iodide were added. The reactions were carried out in an inert gas
atmosphere to avoid oxidation of copper&#173;(I) iodide. Deprotection of
position C5 was then carried out using <italic toggle="yes">p</italic>-toluenesulfonic
acid (<xref rid="sch5" ref-type="fig">Scheme <xref rid="sch5" ref-type="fig"/>
</xref>). This
method proved suitable for the synthesis of the <bold>IVR</bold>/betulinic
acid bioconjugate (compound <bold>15</bold>, yield 33%), but it led
to the decomposition of artesunate. Therefore, to obtain compound <bold>16</bold>, it was necessary to reverse the synthetic procedure (<xref rid="sch5" ref-type="fig">Scheme <xref rid="sch5" ref-type="fig"/>
</xref>). Azide <bold>14</bold> was first subjected to deprotection with <italic toggle="yes">p</italic>-toluenesulfonic
acid and then used in a click reaction with the propargyl ester of
artesunate. This approach allowed the synthesis of compound <bold>16</bold> with a click reaction yield of 63% (<xref rid="sch5" ref-type="fig">Scheme <xref rid="sch5" ref-type="fig"/>
</xref>).</p><p>Purity and structure of the synthesized <bold>IVR</bold> bioconjugates
were determined using spectroscopic (<sup>1</sup>H NMR, <sup>13</sup>C NMR) and spectrometric (ESI-MS) methods. In the <sup>13</sup>C
NMR spectra of <bold>IVR</bold> bioconjugates, the signals of the
highest analytical significance were assigned to the newly introduced
carbonyl group of the carbonate, urethane, or ester moiety at position
C13. Depending on the type of substituent, the signal from the ester
group appeared in the range of 176.3&#8211;165.3 ppm. The signals
from the carbonate group were detected in the range of 153.9&#8211;154.6
ppm, while the signal from the urethane group of compound <bold>8</bold> appeared at 158.4 ppm. The signals from the lactone group at position
C1 were observed in the range of 173.4&#8211;168.3 ppm. In the <sup>1</sup>H NMR spectra of the click derivatives (compounds <bold>15</bold> and <bold>16</bold>), as well as metronidazole bioconjugate <bold>12</bold>, a characteristic, intensive singlet originating from the
hydrogen atom of the triazole/imidazole ring emerged in the narrow
range of 7.88&#8211;7.78 ppm. The ESI-MS analysis confirmed the formation
of the desired products, with [M + Na]<sup>+</sup> or [M + H]<sup>+</sup> as the main peak (intensity = 100%). The NMR and ESI-MS spectra
of all novel <bold>IVR</bold> derivatives are included in the Supporting
Information (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.5c02998/suppl_file/ao5c02998_si_001.pdf" ext-link-type="uri">Figures S1&#8211;S23</ext-link>).</p></sec><sec id="sec2.2"><label>2.2</label><title>Biological Activity</title><sec id="sec2.2.1"><label>2.2.1</label><title>Trypanocidal Activity</title><p>The trypanocidal
and cytotoxic activities of the newly synthesized <bold>IVR</bold> bioconjugates and their conjugation partners were determined for
bloodstream forms of and human myeloid HL-60 cells in vitro using the resazurin cell
viability assay as previously described.<xref rid="ref29" ref-type="bibr"/> For most bioconjugates (<bold>4&#8211;12</bold>), the trypanocidal
activity was found to be only slightly better than that of <bold>IVR</bold>, with 50% growth inhibition (GI<sub>50</sub>) values ranging between
1.3&#8211;2.4 &#956;M (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>). In the case of bioconjugates <bold>4</bold>, <bold>5</bold>, <bold>6</bold>, <bold>7</bold>, and <bold>10</bold>, the observed
antitrypanosomal activity was between that of <bold>IVR</bold> and
the corresponding conjugation partner. As <italic toggle="yes">N</italic>
<bold>-deacetylthiocolchicine</bold>, <bold>azidothymidine</bold>, and <bold>metronidazole</bold> displayed trypanocidal activities with GI<sub>50</sub> values &gt;10 &#956;M (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>), it may be suggested that these conjugation
partners
can enhance the trypanocidal activity of <bold>IVR</bold>. The antitrypanosomal
activity of the bioconjugate <bold>15</bold> (GI<sub>50</sub> = 21.9
&#956;M) was lower than that of <bold>IVR</bold> and its conjugation
partner (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>),
suggesting that the combination of <bold>IVR</bold> and betulinic
acid reduces their individual effectiveness when linked together.
An encouraging result was obtained for bioconjugate <bold>16</bold> (GI<sub>50</sub> = 0.39 &#956;M) as its antitrypanosomal activity
was 7 times and 9 times stronger than those of <bold>IVR</bold> and <bold>artesunate</bold>, respectively (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>), indicating synergistic action of the two
partners. Since the trypanocidal activity of an equimolar mixture
of <bold>IVR</bold> and <bold>artesunate</bold> was 23 times lower
than that of <bold>16</bold> (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>), it can be concluded that <bold>IVR</bold> and artesunate
act synergistically only if linked together. The cytotoxic activity
of the bioconjugates was found to be lower compared with their trypanocidal
activity (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>).
Bioconjugates <bold>6</bold> and <bold>15</bold> displayed the strongest
and lowest cytotoxic activity with GI<sub>50</sub> values of 4.0 and
&gt;100 &#956;M, respectively (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>). Except for <bold>7</bold> and <bold>15</bold>, all
other bioconjugates exhibited lower GI50 values towards HL-60 cell
line than <bold>IVR</bold> (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>). All conjugation partners displayed low (<bold>betulinic
acid</bold> and <bold>artesunate</bold>) or no cytotoxic activity
(<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>).</p><table-wrap position="float" id="tbl1" orientation="portrait"><label>1</label><caption><title>GI<sub>50</sub> Values and Ratios
of <bold>IVR</bold> Conjugates and Conjugation Partners for and HL-60 Cells</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">
<italic toggle="yes">T. brucei</italic>
<hr/></th><th align="center" char="&#xB1;" colspan="1" rowspan="1">HL-60<hr/></th><th align="center" char="." colspan="1" rowspan="1">selectivity<hr/></th><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">
<italic toggle="yes">T. brucei</italic>
<hr/></th><th align="center" colspan="1" rowspan="1">HL-60<hr/></th><th align="center" char="." colspan="1" rowspan="1">selectivity<hr/></th></tr><tr><th align="left" colspan="1" rowspan="1">compound</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">GI<sub>50</sub> (&#956;M)<xref rid="t1fn1" ref-type="table-fn"/>
</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">GI<sub>50</sub> (&#956;M)<xref rid="t1fn1" ref-type="table-fn"/>
</th><th align="center" char="." colspan="1" rowspan="1">GI<sub>50</sub> ratio<xref rid="t1fn2" ref-type="table-fn"/>
</th><th align="left" colspan="1" rowspan="1">compound</th><th align="center" colspan="1" rowspan="1">GI<sub>50</sub> (&#956;M)<xref rid="t1fn1" ref-type="table-fn"/>
</th><th align="center" colspan="1" rowspan="1">GI<sub>50</sub> (&#956;M)<xref rid="t1fn1" ref-type="table-fn"/>
</th><th align="center" char="." colspan="1" rowspan="1">GI<sub>50</sub> ratio<xref rid="t1fn2" ref-type="table-fn"/>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>1 (IVR)</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">2.9&#160;&#177;&#160;0.1</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">30.0&#160;&#177;&#160;1.1</td><td align="char" char="." colspan="1" rowspan="1">10.3</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr></tbody></table><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th colspan="4" align="left" rowspan="1">bioconjugates</th><th colspan="4" align="left" rowspan="1">conjugation partner</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>4</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">2.1&#160;&#177;&#160;0.3</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">21.7&#160;&#177;&#160;11.4</td><td align="char" char="." colspan="1" rowspan="1">10.3</td><td align="left" colspan="1" rowspan="1">
<bold>quinine</bold>
</td><td align="left" colspan="1" rowspan="1">1.1 &#177; 0.3</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">&gt;90.9</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>5</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">1.3
&#177; 0.4</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">22.9 &#177; 11.2</td><td align="char" char="." colspan="1" rowspan="1">17.6</td><td align="left" colspan="1" rowspan="1">
<bold>quinidine</bold>
</td><td align="left" colspan="1" rowspan="1">0.32&#160;&#177;&#160;0.04</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">&gt;312.5</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>6</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">1.8 &#177; 0.4</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">4.0 &#177; 1.0</td><td align="char" char="." colspan="1" rowspan="1">2.2</td><td align="left" colspan="1" rowspan="1">
<bold>cinchonine</bold>
</td><td align="left" colspan="1" rowspan="1">1.7 &#177; 0.6</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">&gt;58.8</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>7</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">2.3
&#177; 0.3</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">47.2 &#177; 3.7</td><td align="char" char="." colspan="1" rowspan="1">20.5</td><td align="left" colspan="1" rowspan="1">
<bold>cinchonidine</bold>
</td><td align="left" colspan="1" rowspan="1">2.1 &#177; 0.6</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">&gt;47.6</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>8</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">1.4 &#177; 0.5</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">10.1 &#177; 4.9</td><td align="char" char="." colspan="1" rowspan="1">7.2</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">
<bold>N</bold>
</italic>
<bold>-deacetylthiocolchicine</bold>
</td><td align="left" colspan="1" rowspan="1">17.4 &#177; 4.3</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">&gt;5.7</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>10</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">2.4
&#177; 0.5</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">19.1 &#177; 9.1</td><td align="char" char="." colspan="1" rowspan="1">8.0</td><td align="left" colspan="1" rowspan="1">
<bold>floxuridine</bold>
</td><td align="left" colspan="1" rowspan="1">2.2 &#177; 0.4</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">&gt;45.5</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>11</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">2.0 &#177; 0.8</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">11.1 &#177;
4.1</td><td align="char" char="." colspan="1" rowspan="1">5.6</td><td align="left" colspan="1" rowspan="1">
<bold>azidothymidine</bold>
</td><td align="left" colspan="1" rowspan="1">19.1 &#177; 8.1</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">&gt;5.2</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>12</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">2.3 &#177; 0.3</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">9.2 &#177; 3.4</td><td align="char" char="." colspan="1" rowspan="1">4.0</td><td align="left" colspan="1" rowspan="1">
<bold>metronidazole</bold>
</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">&#8764;1.0</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>15</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">21.9 &#177; 2.1</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">&gt;4.6</td><td align="left" colspan="1" rowspan="1">
<bold>betulinic
acid</bold>
</td><td align="left" colspan="1" rowspan="1">15.4 &#177; 4.4</td><td align="left" colspan="1" rowspan="1">42.5&#160;&#177;&#160;2.5</td><td align="char" char="." colspan="1" rowspan="1">2.8</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.39 &#177; 0.2</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">18.0 &#177; 6.0</td><td align="char" char="." colspan="1" rowspan="1">46.2</td><td align="left" colspan="1" rowspan="1">
<bold>artesunate</bold>
</td><td align="left" colspan="1" rowspan="1">3.6 &#177; 0.2</td><td align="left" colspan="1" rowspan="1">30.8 &#177; 9.0</td><td align="char" char="." colspan="1" rowspan="1">8.6</td></tr><tr><td align="left" colspan="1" rowspan="1">IVR&#160;+&#160;artesunate</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">9.0 &#177; 3.5</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>suramin</bold>
<xref rid="t1fn3" ref-type="table-fn"/>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.039 &#177; 0.004</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">&gt;2564</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>ethidium bromide</bold>
<xref rid="t1fn3" ref-type="table-fn"/>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.046 &#177; 0.008</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">9.3 &#177; 2.6</td><td align="char" char="." colspan="1" rowspan="1">202</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>Data shown are mean values &#177;
SD of three independent experiments.</p></fn><fn id="t1fn2"><label>b</label><p>GI<sub>50</sub> ratio = GI<sub>50</sub>(HL-60)/GI<sub>50</sub> ().</p></fn><fn id="t1fn3"><label>c</label><p>Reference controls.</p></fn></table-wrap-foot></table-wrap><p>The selectivity index (ratio of cytotoxic to trypanocidal
activity)
of all bioconjugates was found to be in the range of moderate values
(&lt;100) (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>).
Only compounds <bold>5</bold>, <bold>7</bold>, and <bold>16</bold> had a better selectivity index than <bold>IVR</bold>, with <bold>16</bold> having the best one due to its increased trypanocidal activity
(<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>). On the other
hand, the cinchona bark alkaloids (<bold>quinine</bold>, <bold>quinidine</bold>, <bold>cinchonine</bold>, and <bold>cinchonidine</bold>) had a better
selectivity index than bioconjugate <bold>16</bold>, which can be
attributed to their noncytotoxicity (GI<sub>50</sub> &gt; 100 &#956;M, <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>). Encouraging, however,
is the finding that <bold>16</bold> is nontoxic against normal cells
(HaCaT, <xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). Using
the cytotoxicity of normal cells (HaCaT) as the reference value, the
selectivity index for 16 would then be &gt;256. As the commercial
drugs
suramin and ethidium bromide (homidium bromide) used for the treatment
of human and animal African trypanosomiasis, respectively, display
10 times higher trypanocidal activity, their selectivity indices are
much higher (&gt;200) (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>).</p><table-wrap position="float" id="tbl2" orientation="portrait"><label>2</label><caption><title>Antiproliferative Activity (IC<sub>50</sub>, &#956;M) of <bold>IVR</bold>, its Conjugates, and Conjugation
Partners<xref rid="t2fn1" ref-type="table-fn"/>
</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th colspan="8" align="center" char="&#xB1;" rowspan="1">cancer
cells<hr/></th><th align="center" colspan="1" rowspan="1">normal cells<hr/></th></tr><tr><th align="left" colspan="1" rowspan="1">&#160;</th><th colspan="2" align="center" char="&#xB1;" rowspan="1">PC3<hr/></th><th colspan="2" align="center" rowspan="1">MDA-MB-231<hr/></th><th colspan="2" align="center" rowspan="1">A549<hr/></th><th colspan="2" align="center" rowspan="1">HCT-116<hr/></th><th align="center" colspan="1" rowspan="1">HaCaT<hr/></th></tr><tr><th align="left" colspan="1" rowspan="1">compound</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">IC<sub>50</sub>
</th><th align="center" char="." colspan="1" rowspan="1">SI<xref rid="t2fn2" ref-type="table-fn"/>
</th><th align="center" colspan="1" rowspan="1">IC<sub>50</sub>
</th><th align="center" char="." colspan="1" rowspan="1">SI<xref rid="t2fn2" ref-type="table-fn"/>
</th><th align="center" colspan="1" rowspan="1">IC<sub>50</sub>
</th><th align="center" char="." colspan="1" rowspan="1">SI<xref rid="t2fn2" ref-type="table-fn"/>
</th><th align="center" colspan="1" rowspan="1">IC<sub>50</sub>
</th><th align="center" char="." colspan="1" rowspan="1">SI<xref rid="t2fn2" ref-type="table-fn"/>
</th><th align="center" colspan="1" rowspan="1">IC<sub>50</sub>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><bold>1</bold> (<bold>IVR</bold>)</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">33.9&#160;&#177;&#160;6.3</td><td align="char" char="." colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">8.7&#160;&#177;&#160;3.2</td><td align="char" char="." colspan="1" rowspan="1">1.4</td><td align="left" colspan="1" rowspan="1">7.2
&#177; 1.4</td><td align="char" char="." colspan="1" rowspan="1">1.8</td><td align="left" colspan="1" rowspan="1">9.9 &#177; 1.1</td><td align="char" char="." colspan="1" rowspan="1">1.3</td><td align="left" colspan="1" rowspan="1">12.6 &#177; 4.3</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>4</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">13.1 &#177; 3.5</td><td align="char" char="." colspan="1" rowspan="1">2.0</td><td align="left" colspan="1" rowspan="1">16.3 &#177; 4.9</td><td align="char" char="." colspan="1" rowspan="1">1.6</td><td align="left" colspan="1" rowspan="1">56.3&#160;&#177;&#160;5.1</td><td align="char" char="." colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">16.7&#160;&#177;&#160;2.3</td><td align="char" char="." colspan="1" rowspan="1">1.6</td><td align="left" colspan="1" rowspan="1">26.8&#160;&#177;&#160;4.9</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>5</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">12.4 &#177; 2.1</td><td align="char" char="." colspan="1" rowspan="1">1.2</td><td align="left" colspan="1" rowspan="1">10.1
&#177; 1.4</td><td align="char" char="." colspan="1" rowspan="1">1.5</td><td align="left" colspan="1" rowspan="1">42.3 &#177; 0.5</td><td align="char" char="." colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">13.8 &#177; 3.5</td><td align="char" char="." colspan="1" rowspan="1">1.1</td><td align="left" colspan="1" rowspan="1">14.9 &#177; 1.6</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>6</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">4.1 &#177; 1.7</td><td align="char" char="." colspan="1" rowspan="1">3.6</td><td align="left" colspan="1" rowspan="1">13.8 &#177;
1.6</td><td align="char" char="." colspan="1" rowspan="1">1.1</td><td align="left" colspan="1" rowspan="1">35.3 &#177; 6.5</td><td align="char" char="." colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">12.2 &#177; 2.8</td><td align="char" char="." colspan="1" rowspan="1">1.2</td><td align="left" colspan="1" rowspan="1">14.6 &#177; 1.6</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>7</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">7.2 &#177; 3.8</td><td align="char" char="." colspan="1" rowspan="1">7.0</td><td align="left" colspan="1" rowspan="1">22.4 &#177; 1.2</td><td align="char" char="." colspan="1" rowspan="1">2.2</td><td align="left" colspan="1" rowspan="1">13.6 &#177; 1.1</td><td align="char" char="." colspan="1" rowspan="1">3.7</td><td align="left" colspan="1" rowspan="1">20.1 &#177; 3.7</td><td align="char" char="." colspan="1" rowspan="1">2.5</td><td align="left" colspan="1" rowspan="1">50.3 &#177;
4.9</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>8</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">85.1 &#177;
9.8</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.2</td><td align="left" colspan="1" rowspan="1">6.6 &#177; 0.6</td><td align="char" char="." colspan="1" rowspan="1">&gt;15.2</td><td align="left" colspan="1" rowspan="1">12.4 &#177; 2.6</td><td align="char" char="." colspan="1" rowspan="1">&gt;8.1</td><td align="left" colspan="1" rowspan="1">7.5 &#177; 1.6</td><td align="char" char="." colspan="1" rowspan="1">&gt;13.3</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>10</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">7.8 &#177; 2.9</td><td align="char" char="." colspan="1" rowspan="1">2.0</td><td align="left" colspan="1" rowspan="1">13.2 &#177; 1.1</td><td align="char" char="." colspan="1" rowspan="1">1.2</td><td align="left" colspan="1" rowspan="1">15.5 &#177; 3.2</td><td align="char" char="." colspan="1" rowspan="1">1.0</td><td align="left" colspan="1" rowspan="1">14.3 &#177;
1.9</td><td align="char" char="." colspan="1" rowspan="1">1.1</td><td align="left" colspan="1" rowspan="1">15.4 &#177; 1.1</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>11</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">8.1 &#177; 3.2</td><td align="char" char="." colspan="1" rowspan="1">3.2</td><td align="left" colspan="1" rowspan="1">12.5 &#177; 1.5</td><td align="char" char="." colspan="1" rowspan="1">2.1</td><td align="left" colspan="1" rowspan="1">8.2 &#177; 1.9</td><td align="char" char="." colspan="1" rowspan="1">3.2</td><td align="left" colspan="1" rowspan="1">7.7 &#177; 3.1</td><td align="char" char="." colspan="1" rowspan="1">3.4</td><td align="left" colspan="1" rowspan="1">26.1 &#177; 3.3</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>12</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">5.9 &#177; 1.7</td><td align="char" char="." colspan="1" rowspan="1">4.5</td><td align="left" colspan="1" rowspan="1">13.6 &#177; 3.7</td><td align="char" char="." colspan="1" rowspan="1">2.0</td><td align="left" colspan="1" rowspan="1">13.2 &#177;
3.4</td><td align="char" char="." colspan="1" rowspan="1">2.0</td><td align="left" colspan="1" rowspan="1">9.1 &#177; 0.6</td><td align="char" char="." colspan="1" rowspan="1">2.9</td><td align="left" colspan="1" rowspan="1">26.7 &#177; 2.6</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>15</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">93.9 &#177; 6.4</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.1</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">&#8764;1.0</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">&#8764;1.0</td><td align="left" colspan="1" rowspan="1">70.1 &#177; 6.4</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.4</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">20.8 &#177; 7.2</td><td align="char" char="." colspan="1" rowspan="1">&gt;4.8</td><td align="left" colspan="1" rowspan="1">13.0 &#177; 4.1</td><td align="char" char="." colspan="1" rowspan="1">&gt;7.7</td><td align="left" colspan="1" rowspan="1">3.8 &#177; 1.3</td><td align="char" char="." colspan="1" rowspan="1">&gt;26.3</td><td align="left" colspan="1" rowspan="1">4.5 &#177;
0.6</td><td align="char" char="." colspan="1" rowspan="1">&gt;22.2</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>quinine</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">56.3 &#177; 7.2</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.8</td><td align="left" colspan="1" rowspan="1">54.4 &#177; 7.0</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.8</td><td align="left" colspan="1" rowspan="1">56.4 &#177; 3.2</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.8</td><td align="left" colspan="1" rowspan="1">32.8 &#177;
3.8</td><td align="char" char="." colspan="1" rowspan="1">&gt;3.0</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>quinidine</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">86.1 &#177; 1.2</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.2</td><td align="left" colspan="1" rowspan="1">76.2 &#177; 4.6</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.3</td><td align="left" colspan="1" rowspan="1">55.8 &#177; 5.3</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.8</td><td align="left" colspan="1" rowspan="1">67.4 &#177;
8.9</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.5</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>cinchonine</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">74.3 &#177; 5.4</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.3</td><td align="left" colspan="1" rowspan="1">65.3 &#177; 2.8</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.5</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">&#8764;1.0</td><td align="left" colspan="1" rowspan="1">78.2 &#177;
5.8</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.3</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>cinchonidine</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">86.7 &#177; 3.9</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.2</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">&#8764;1.0</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">&#8764;1.0</td><td align="left" colspan="1" rowspan="1">87.1 &#177;
12.1</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.1</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">N</italic>
<bold>-deacetylthiocolchicine</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">56.1 &#177; 2.5</td><td align="char" char="." colspan="1" rowspan="1">1.6</td><td align="left" colspan="1" rowspan="1">84.2 &#177;
7.1</td><td align="char" char="." colspan="1" rowspan="1">1.0</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.9</td><td align="left" colspan="1" rowspan="1">70.3 &#177; 5.9</td><td align="char" char="." colspan="1" rowspan="1">1.2</td><td align="left" colspan="1" rowspan="1">87.4 &#177;
10.4</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>floxuridine</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">15.7 &#177; 3.3</td><td align="char" char="." colspan="1" rowspan="1">1.5</td><td align="left" colspan="1" rowspan="1">22.2 &#177; 3.4</td><td align="char" char="." colspan="1" rowspan="1">1.1</td><td align="left" colspan="1" rowspan="1">26.4 &#177; 3.8</td><td align="char" char="." colspan="1" rowspan="1">0.9</td><td align="left" colspan="1" rowspan="1">11.7 &#177; 4.2</td><td align="char" char="." colspan="1" rowspan="1">2.1</td><td align="left" colspan="1" rowspan="1">24.3 &#177;
7.3</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>azidothymidine</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">64.3 &#177; 3.7</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.6</td><td align="left" colspan="1" rowspan="1">52.2 &#177; 4.1</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.9</td><td align="left" colspan="1" rowspan="1">72.1 &#177; 11.6</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.4</td><td align="left" colspan="1" rowspan="1">60.2 &#177; 9.7</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.7</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>metronidazole</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">57.0 &#177;
6.1</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.8</td><td align="left" colspan="1" rowspan="1">14.9 &#177; 3.9</td><td align="char" char="." colspan="1" rowspan="1">&gt;6.7</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">&#8764;1.0</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">&#8764;1.0</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>betulinic acid</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">66.6 &#177;
2.3</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.5</td><td align="left" colspan="1" rowspan="1">46.5 &#177; 4.6</td><td align="char" char="." colspan="1" rowspan="1">&gt;2.2</td><td align="left" colspan="1" rowspan="1">98.1 &#177; 3.1</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.0</td><td align="left" colspan="1" rowspan="1">80.1 &#177; 6.1</td><td align="char" char="." colspan="1" rowspan="1">&gt;1.2</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>artesunate</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">48.5 &#177;
5.7</td><td align="char" char="." colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">12.6 &#177; 3.9</td><td align="char" char="." colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">24.0 &#177; 6.9</td><td align="char" char="." colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">37.8 &#177; 4.2</td><td align="char" char="." colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">5.7 &#177; 0.1</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>IVR + artesunate</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">1.8
&#177; 0.5</td><td align="char" char="." colspan="1" rowspan="1">8.9</td><td align="left" colspan="1" rowspan="1">22.5 &#177; 2.6</td><td align="char" char="." colspan="1" rowspan="1">0.7</td><td align="left" colspan="1" rowspan="1">2.4 &#177; 0.7</td><td align="char" char="." colspan="1" rowspan="1">6.7</td><td align="left" colspan="1" rowspan="1">1.7 &#177; 0.2</td><td align="char" char="." colspan="1" rowspan="1">9.5</td><td align="left" colspan="1" rowspan="1">16.1 &#177; 2.9</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>doxorubicin</bold>
<xref rid="t2fn3" ref-type="table-fn"/>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.6 &#177; 0.02</td><td align="char" char="." colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">1.83
&#177; 0.1</td><td align="char" char="." colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.63 &#177; 0.2</td><td align="char" char="." colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">0.6 &#177; 0.02</td><td align="char" char="." colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">0.29 &#177; 0.1</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><label>a</label><p>Data are expressed as mean &#177;
SD; IC<sub>50</sub> (&#956;M), the concentration of the compound
that corresponds to a 50% growth inhibition of the cell line (compared
to the control) after culturing the cells for 72 h with the individual
compound; PC3, human metastatic prostate cancer cell line; MDA-MB-231,
human triple-negative breast cancer cell line; A549, human lung cancer
cell line; HCT-116, human primary colon cancer cell line; HaCaT, human
immortalized keratinocyte cell line.</p></fn><fn id="t2fn2"><label>b</label><p>SI (selectivity index) was calculated
using the formula: SI = IC<sub>50</sub> for normal cell line (HaCaT)/IC<sub>50</sub> for respective cancer cell line (PC3, MDA-MB-231, A549,
or HCT-116). Briefly, an SI &gt; 1.0 indicates that the compounds
exhibit
greater potency against cancer cells than toxicity toward nontumor
cells.<xref rid="ref35" ref-type="bibr"/>
</p></fn><fn id="t2fn3"><label>c</label><p>Reference compound commonly used
in cancer treatment.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2.2.2"><label>2.2.2</label><title>Antiproliferative Activity</title><p>The
antiproliferative activities of <bold>IVR</bold>, its newly synthesized
bioconjugates, and its precursors were evaluated against four human
cancer cell lines: PC3 (metastatic prostate cancer), MDA-MB-231 (triple-negative
breast adenocarcinoma), A549 (lung cancer), and HCT-116 (primary colon
cancer) using the MTT colorimetric assay (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). Additionally, to assess the selectivity
of these compounds toward cancer cells, we included an immortalized
keratinocyte cell line from adult human skin (HaCaT) in the antiproliferative
activity tests. Doxorubicin served as the reference anticancer drug.
First, it is important to highlight the antiproliferative activity
exhibited by <bold>IVR</bold>. This drug demonstrates the highest
activity among all compounds used for bioconjugation across all tested
cell lines, with the exception of <bold>floxuridine</bold>, which
displays a lower IC<sub>50</sub> value than <bold>IVR</bold> for the
PC3 cell line (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). However, it should be noted that <bold>IVR</bold> exhibits the
highest cytotoxicity toward the HaCaT cell line among all compounds
used for bioconjugation, except <bold>artesunate</bold>. Despite that, <bold>IVR</bold> selectively targets cancer cells from the MDA-MB-231,
A549, and HCT-116 lines more effectively than the reference HaCaT
cell line (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>).
Consequently, the selectivity indices of <bold>IVR</bold> are comparable
to those of the other conjugation partners. Second, the bioconjugates
had, in most cases, lower biological activity than <bold>IVR</bold>. The <bold>IVR</bold> bioconjugates with cinchona bark alkaloids
(compounds <bold>4&#8211;8</bold>) generally showed reduced antiproliferative
activity compared to unmodified <bold>IVR</bold> (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). However, an interesting result
was observed for the PC3 cell line, which was particularly resistant
to the effects of <bold>IVR</bold> and cinchona bark alkaloids. The
obtained bioconjugates are effective against the PC3 cancer cell line,
with <bold>6</bold> showing an IC<sub>50</sub> value of 4.1 &#956;M,
making it one of the most active compounds in the entire series of
bioconjugates (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>).</p><p>Furthermore, most <bold>IVR</bold> bioconjugates with cinchona
bark alkaloids showed satisfactory selectivity index values, with
compound <bold>7</bold> reaching a value of 7.0 (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). Although <italic toggle="yes">N</italic>
<bold>-deacetylthiocolchicine</bold> exhibited low bioactivity across
all tested cancer cell lines, the corresponding bioconjugate (compound <bold>8</bold>) had IC<sub>50</sub> values comparable to those of unmodified <bold>IVR</bold>. In addition, compound <bold>8</bold> showed high selectivity,
as it was completely nontoxic to the reference HaCaT cell line (SI
&gt; 15.2 for the MDA-MB-231 cell line). <bold>IVR</bold> bioconjugates
with the nucleoside analogs and <bold>metronidazole</bold> (compounds <bold>10&#8211;12</bold>) exhibited the highest antiproliferative activity
against the PC3 cancer cell line (IC<sub>50</sub> = 5.9&#8211;8.1
&#956;M), comparable to that of cinchona bark alkaloids, which indicates
that the replacement of the sugar moiety at position C13 of <bold>IVR</bold> with small-molecular conjugation partners enhanced their
activity against the PC3 cell line (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>).</p><p>Bioconjugates with partners characterized
by high molecular weight
and greater steric hindrance, such as <italic toggle="yes">N</italic>-<bold>deacetylthiocolchicine</bold> or <bold>betulinic acid</bold>, seemed to be ineffective against
cancer cells of the PC3 line. Moreover, the <bold>IVR</bold> bioconjugate
with <bold>betulinic acid</bold> (compound <bold>15</bold>) proved
to be the least active compound from the entire series (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). This is likely due to its
low bioavailability, as this hybrid showed no activity against either
cancer cell lines or the reference cell line. A particularly promising
compound was the <bold>IVR</bold> bioconjugate with <bold>artesunate</bold> (compound <bold>16</bold>). This hybrid proved to be not only the
most active bioconjugate from the entire series (IC<sub>50</sub> =
3.8 &#956;M against the A549 cell line and IC<sub>50</sub> = 4.5
&#956;M against the HCT-116 cell line), but it also showed no toxicity
against the HaCaT cell line (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). This indicates that compound <bold>16</bold> is
highly selective (SI &gt; 26.3 against the A549 cell line) and could
be a lead compound for further drug development.</p><p>Inspired by
the high potential of compound <bold>16</bold>, we
evaluated the antiproliferative activity of an equimolar mixture of <bold>IVR</bold> and <bold>artesunate</bold> (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). As shown, the results are ambiguous. In
the case of the PC3 cell line, the mixture of the two compounds exhibited
significantly greater activity compared to that of compound <bold>16, IVR</bold>, and <bold>artesunate</bold> tested individually (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). For the A549 and
HCT-116 cell lines, the mixture and the bioconjugate <bold>16</bold> demonstrated comparable levels of activity, slightly in favor of
the mixture. In contrast, for the MDA-MB-231 cell line, compound <bold>16</bold> showed superior antiproliferative activity relative to
that of the drug combination. Despite these inconsistencies, it is
important to note the differences in cytotoxicity with respect to
the HaCaT reference cell line. Bioconjugation of the two agents effectively
mitigated the negative effects of both drugs on noncancerous cells,
underscoring the beneficial outcomes of the bioconjugation strategy.</p><p>Finally, although doxorubicin showed strong antiproliferative activity
against all tested cancer cell lines, it is important to emphasize
its high cytotoxicity toward HaCaT cells (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). In all cases, the SI values of doxorubicin
were lower than 1.0, indicating that the compound preferentially targets
healthy cells over cancerous ones (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). In contrast, almost all bioconjugates
displayed SI values greater than 1.0, underscoring their high anticancer
potential (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>).</p></sec></sec></sec><sec id="sec3"><label>3</label><title>Conclusions</title><p>A series of new <bold>IVR</bold> bioconjugates with partners exhibiting
high antitumor or antimicrobial activity have been synthesized. These
partners included four cinchona bark alkaloids, nucleoside analogs,
metronidazole, <italic toggle="yes">N</italic>-deacetylthiocolchicine, betulinic
acid, and artesunate. The hybrids were obtained using three different
synthetic procedures, allowing the introduction of various linkers
such as carbonate, urethane, or a 1,2,3-triazole ring. All obtained
bioconjugates, along with their respective conjugation partners, were
evaluated in vitro for their activity against the protozoan parasite . For most bioconjugates, the trypanocidal
activity was slightly better than that of <bold>IVR,</bold> with GI<sub>50</sub> values ranging between 1.3&#8211;2.4 &#956;M. For the
bioconjugates <bold>4</bold>, <bold>5</bold>, <bold>6</bold>, <bold>7</bold>, and <bold>10</bold>, the antitrypanosomal activity was
between that of <bold>IVR</bold> and the corresponding conjugation
partner. In addition to the antitrypanosomal studies, in vitro experiments
were also conducted against various cancer cell lines. It has been
shown that the conjugation of <bold>IVR</bold> with cinchona bark
alkaloids, nucleosides, or metronidazole is an effective method to
enhance the antiproliferative activity of <bold>IVR</bold> against
the PC3 cancer cell line, which was most resistant to the action of <bold>IVR</bold> and the conjugation partners. On the other hand, compound <bold>8</bold> exhibited antiproliferative activity similar to that of <bold>IVR</bold>, but its lack of toxicity against the HaCaT reference
cell line suggests that it is a highly selective anticancer agent.
In both antiparasitic and anticancer activity assays, compound <bold>16</bold> (<bold>IVR</bold>-artesunate bioconjugate) showed the highest
activity. This hybrid was not only several times more active than
its components but also demonstrated low toxicity against the reference
cell line. Moreover, trypanocidal studies of the <bold>IVR</bold>-artesunate
equimolar mixture revealed that the synergistic effect of the combination
of these two drugs was observed only after conjugation. A mixture
of the two compounds acts antagonistically, showing lower activity
than <bold>IVR</bold> or artesunate alone. Analogous antiproliferative
studies gave more variable results; however, compound <bold>16</bold> proved to be significantly less cytotoxic against noncancerous cells
than the combination of <bold>IVR</bold> and artesunate. These observations
confirm that conjugation of <bold>IVR</bold> is a promising approach
to develop new bioactive compounds with potential applications in
anticancer and antiparasitic therapies.</p></sec><sec id="sec4"><label>4</label><title>Experimental Section</title><sec id="sec4.1"><label>4.1</label><title>General Procedure</title><p>Ivermectin (<bold>IVR</bold>, form B1a) was purchased from Trimen Chemicals S.A. All
other reagents were commercially available and purchased from two
sources, Merck or Trimen Chemicals S.A., and were used without further
purification. A detailed description of the general procedures, measurement
parameters, and equipment can be found in the Supporting Information.</p></sec><sec id="sec4.2"><label>4.2</label><title>Synthesis of Ivermectin Aglycone (Compound <bold>2</bold>)</title><p>
<bold>IVR</bold> (4.95 g, 5.66 mmol, 1.0 equiv)
was dissolved in methanol (79.2 mL) and the solution was cooled in
an ice bath. Concentrated sulfuric acid (0.8 mL) was then added dropwise
to the reaction mixture. The solution changed color to greenish, and
after a few hours, it turned yellow. After 20 h, the reaction mixture
was concentrated by using a rotary evaporator, diluted with CH<sub>2</sub>Cl<sub>2</sub>, and extracted with an aqueous sodium carbonate
solution (0.1 M). The organic layers were then concentrated under
reduced pressure. The product was purified on silica gel using the
CombiFlash system (0% &#8594; 30% EtOAc/CHCl<sub>3</sub>), yielding
pure aglycone <bold>2</bold> as a clear oil. After two evaporation
steps with <italic toggle="yes">n</italic>-pentane to remove any remaining solvent,
the oily product was fully converted to a white, amorphous solid (2.79
g, 84% yield). The spectroscopic data were in agreement with previously
published data.<xref rid="ref15" ref-type="bibr"/>
</p></sec><sec id="sec4.3"><label>4.3</label><title>Protection of the C5 Hydroxyl Group of Ivermectin
Aglycone (Compound <bold>3</bold>)</title><p>To a stirred solution
of <bold>2</bold> (2.00 g, 3.41 mmol, 1.0 equiv) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (40 mL), imidazole (2.32 g, 34.07 mmol, 10.0
equiv) was added. Once the imidazole had dissolved, <italic toggle="yes">tert</italic>-butyldimethylsilyl chloride (1.13 g, 7.50 mmol, 2.2 equiv) was added
in one portion. The reaction mixture was stirred at room temperature
for 24 h. After this period, the reaction mixture was concentrated
to dryness using a rotary evaporator. The product was then purified
on silica gel using the CombiFlash system (0% &#8594; 10% EtOAc/CHCl<sub>3</sub>), yielding pure product <bold>3</bold> as a clear oil. After
two evaporation steps with <italic toggle="yes">n</italic>-pentane to remove residual
solvent, the oily product was fully converted to a yellow amorphous
solid (2.17 g, 91% yield). The spectroscopic data were in agreement
with previously published data.<xref rid="ref15" ref-type="bibr"/>
</p></sec><sec id="sec4.4"><label>4.4</label><title>Synthesis of <italic toggle="yes">N</italic>-Deacetylthiocolchicine</title><p>To a mixture of colchicine (500 mg, 1.25 mmol) in MeOH (5 mL) was
added a sodium methanethiolate solution (21% in H<sub>2</sub>O, 0.83
mL, 2.5 mmol). The mixture was stirred at room temperature, and the
reaction progress was monitored by TLC. After 24 h, the reaction mixture
was quenched by adding water (150 mL). The mixture was then extracted
four times with CH<sub>2</sub>Cl<sub>2</sub>, and the combined organic
layers were dried over MgSO<sub>4</sub>, filtered, and evaporated
under reduced pressure. The residue was purified by the CombiFlash
system (EtOAc/MeOH, increasing concentration gradient) to yield thiocolchicine
as an amorphous yellow solid (78% yield). Next, a solution of thiocolchicine
(500 mg, 1.18 mmol) in MeOH (3 mL) was treated with a 2 M HCl solution
(5 mL). The mixture was stirred at 90 &#176;C for 72 h, and the reaction
progress was monitored by TLC. Afterward, the solvent was evaporated
under reduced pressure. The residue was purified by CombiFlash system
(EtOAc/MeOH, increasing concentration gradient) to yield <italic toggle="yes">N</italic>-deacetylthiocolchicine (82% yield). The spectroscopic data were
in agreement with previously published data.<xref rid="ref21" ref-type="bibr"/>
</p></sec><sec id="sec4.5"><label>4.5</label><title>General Procedure for the Preparation of Ivermectin
Conjugates with <italic toggle="yes">N</italic>-Deacetylthiocolchicine and Cinchona
Bark Alkaloids (Compounds <bold>4&#8211;8</bold>)</title><p>Precursor <bold>3</bold> (400 mg, 0.57 mmol, 1.0 equiv) was dissolved in anhydrous
THF (20 mL). The solution was then cooled in an ice bath, and triethylamine
(288 mg, 2.85 mmol, 5.0 equiv). Next, triphosgene (85 mg, 0.29 mmol,
0.5 equiv) was added to the reaction mixture in one portion, and stirring
was continued for 1 h. The formation of a white precipitate was observed.
Then, the appropriate conjugation partner (<italic toggle="yes">N</italic>-deacetylthiocolchicine
or cinchona bark alkaloid, 0.86 mmol, 1.5 equiv) was added to the
reaction mixture, and stirring was continued for 24 h. Thereafter,
the reaction mixture was concentrated to dryness using a rotary evaporator,
diluted with CH<sub>2</sub>Cl<sub>2</sub>, and extracted with brine.
The collected organic layers were subsequently concentrated <italic toggle="yes">in vacuo</italic>. Purification on silica gel using the CombiFlash
system (0% &#8594; 100% EtOAc/CHCl<sub>3</sub>) gave the respective
C5-protected bioconjugates as clear oils.</p><p>To remove the C5-protecting
group, the individual hybrids were dissolved in methanol (10 mL) and <italic toggle="yes">para</italic>-toluenesulfonic acid hydrate (80 mg, 0.46 mmol, 1.3
equiv) was added. After 2 h, the organic solvent was evaporated, diluted
with CH<sub>2</sub>Cl<sub>2</sub>, and extracted with an aqueous solution
of sodium carbonate (0.1 M). Next, the collected organic layers were
subsequently concentrated <italic toggle="yes">in vacuo</italic>. Purification
on silica gel using the CombiFlash system (0% &#8594; 100% EtOAc/CHCl<sub>3</sub>) gave the pure products <bold>4&#8211;8</bold> as clear
oils. After twice evaporation to dryness with <italic toggle="yes">n</italic>-pentane,
the oily products were completely converted to white or yellow amorphous
solids.</p><sec id="sec4.5.1"><label>4.5.1</label><title>Ivermectin&#8211;Quinine Conjugate <bold>4</bold>
</title><p>86 mg, 19% yield (over two steps). Isolated as
a white, amorphous solid, a single spot by TLC. UV-active and strains
green with PMA; <sup>1</sup>H NMR (401 MHz, CDCl<sub>3</sub>) &#948;
8.74 (d, <italic toggle="yes">J</italic> = 4.5 Hz, 1H), 8.02 (d, <italic toggle="yes">J</italic> = 9.9 Hz, 1H), 7.40 (d, <italic toggle="yes">J</italic> = 4.6 Hz, 1H), 7.38&#8211;7.34
(m, 2H), 6.30 (d, <italic toggle="yes">J</italic> = 5.2 Hz, 1H), 5.88&#8211;5.83
(m, 1H), 5.83&#8211;5.76 (m, 1H), 5.76&#8211;5.72 (m, 1H), 5.68
(dd, <italic toggle="yes">J</italic> = 14.7, 9.3 Hz, 1H), 5.41 (s, 1H), 5.37&#8211;5.27
(m, 1H), 5.13 (dd, <italic toggle="yes">J</italic> = 10.6, 4.9 Hz, 1H), 4.98 (dd, <italic toggle="yes">J</italic> = 13.7, 8.3 Hz, 2H), 4.87 (s, 1H), 4.66 (qd, <italic toggle="yes">J</italic> = 14.5, 2.1 Hz, 2H), 4.30&#8211;4.26 (m, 1H), 4.25&#8211;4.21
(m, 1H), 3.97&#8211;3.92 (m, 4H), 3.70&#8211;3.62 (m, 1H), 3.33
(q, <italic toggle="yes">J</italic> = 7.9 Hz, 1H), 3.26 (dd, <italic toggle="yes">J</italic> = 4.4, 2.2 Hz, 1H), 3.17 (t, <italic toggle="yes">J</italic> = 11.2 Hz, 2H),
3.04 (dd, <italic toggle="yes">J</italic> = 13.7, 10.2 Hz, 1H), 2.73&#8211;2.52
(m, 4H), 2.35&#8211;0.71 (m, 38H) ppm; <sup>13</sup>C NMR (101 MHz,
CDCl<sub>3</sub>) &#948; 173.4, 158.0, 154.2, 147.3, 144.7, 140.8,
137.8, 136.0, 134.3, 131.8, 126.7, 125.5, 121.9, 119.9, 118.2, 118.0,
117.8, 114.6, 101.1, 97.4, 83.1, 80.3, 79.2, 77.1, 68.4, 68.3, 67.6,
67.0, 59.3, 56.7, 55.6, 45.6, 42.6, 41.3, 39.7, 39.0, 36.8, 35.8,
35.5, 34.2, 34.1, 31.2, 29.2, 28.0, 27.6, 27.4, 23.8, 22.3, 19.9,
18.5, 17.4, 14.5, 14.0, 12.5, 11.8 ppm; ESI-MS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: [M + H]<sup>+</sup> Calcd for C<sub>55</sub>H<sub>73</sub>N<sub>2</sub>O<sub>11</sub>
<sup>+</sup> 938; Found 937; [M + Na]<sup>+</sup> Calcd for C<sub>55</sub>H<sub>72</sub>N<sub>2</sub>NaO<sub>11</sub>
<sup>+</sup> 960; Found 959.</p></sec><sec id="sec4.5.2"><label>4.5.2</label><title>Ivermectin&#8211;Quinidine Conjugate <bold>5</bold>
</title><p>102 mg, 16% yield (over two steps). Isolated as
a white amorphous solid, a single spot by TLC. UV-active and strains
green with PMA; <sup>1</sup>H NMR (401 MHz, CDCl<sub>3</sub>) &#948;
8.69 (d, <italic toggle="yes">J</italic> = 4.6 Hz, 1H), 8.00 (d, <italic toggle="yes">J</italic> = 9.2 Hz, 1H), 7.38&#8211;7.30 (m, 3H), 6.48 (d, <italic toggle="yes">J</italic> = 5.7 Hz, 1H), 6.15&#8211;6.04 (m, 1H), 5.84 (dt, <italic toggle="yes">J</italic> = 10.7, 2.1 Hz, 1H), 5.81&#8211;5.72 (m, 1H), 5.66 (dd, <italic toggle="yes">J</italic> = 14.5, 9.8 Hz, 1H), 5.40 (s, 1H), 5.34&#8211;5.24 (m,
1H), 5.14 (s, 1H), 5.12&#8211;5.09 (m, 1H), 4.98 (dd, <italic toggle="yes">J</italic> = 10.1, 5.2 Hz, 1H), 4.93 (s, 1H), 4.65 (qd, J = 14.5, 2.1 Hz, 2H),
4.28 (d, <italic toggle="yes">J</italic> = 5.8 Hz, 1H), 4.25 (s, 1H), 3.95 (d, <italic toggle="yes">J</italic> = 6.1 Hz, 1H), 3.92 (s, 3H), 3.63&#8211;3.54 (m, 1H),
3.29&#8211;3.21 (m, 2H), 3.15 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H),
2.94 (d, <italic toggle="yes">J</italic> = 9.0 Hz, 2H), 2.90&#8211;2.83 (m, 1H),
2.75 (dt, <italic toggle="yes">J</italic> = 13.3, 8.7 Hz, 1H), 2.67&#8211;2.57
(m, 2H), 2.28 (dd, <italic toggle="yes">J</italic> = 16.5, 8.5 Hz, 1H), 2.21&#8211;2.08
(m, 3H), 2.06&#8211;0.66 (m, 34H) ppm; <sup>13</sup>C NMR (101 MHz,
CDCl<sub>3</sub>) &#948; 173.4, 158.1, 154.2, 147.1, 144.6, 143.3,
140.8, 140.1, 137.8, 135.9, 133.9, 131.7, 127.0, 125.5, 122.1, 119.9,
118.0, 118.0, 117.9, 117.5, 115.0, 100.8, 97.4, 83.2, 80.3, 79.2,
76.9, 68.5, 68.3, 67.6, 66.9, 59.0, 55.5, 49.9, 49.2, 45.6, 41.2,
39.8, 39.1, 36.7, 35.7, 35.4, 34.0, 31.2, 28.0, 27.9, 27.4, 26.3,
22.5, 19.8, 18.6, 17.4, 14.4, 12.5, 11.8 ppm; ESI-MS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: [M + H]<sup>+</sup> Calcd for C<sub>55</sub>H<sub>73</sub>N<sub>2</sub>O<sub>11</sub>
<sup>+</sup> 938; Found
938.</p></sec><sec id="sec4.5.3"><label>4.5.3</label><title>Ivermectin&#8211;Cinchonine Conjugate <bold>6</bold>
</title><p>109 mg, 21% yield (over two steps). Isolated as
a white amorphous solid, a single spot by TLC. UV-active and strains
green with PMA; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#948;
8.84 (d, <italic toggle="yes">J</italic> = 4.5 Hz, 1H), 8.15&#8211;8.10 (m, 2H),
7.74&#8211;7.67 (m, 1H), 7.63&#8211;7.56 (m, 1H), 7.41 (d, <italic toggle="yes">J</italic> = 4.5 Hz, 1H), 6.47 (d, <italic toggle="yes">J</italic> = 6.1 Hz, 1H),
6.14&#8211;6.03 (m, 1H), 5.84&#8211;5.70 (m, 2H), 5.58 (dd, <italic toggle="yes">J</italic> = 13.7, 10.2 Hz, 1H), 5.40 (s, 1H), 5.35&#8211;5.25 (m,
1H), 5.13 (s, 1H), 5.10 (d, <italic toggle="yes">J</italic> = 4.4 Hz, 1H), 4.99
(dd, <italic toggle="yes">J</italic> = 9.6, 5.6 Hz, 1H), 4.92 (s, 1H), 4.64 (qd, <italic toggle="yes">J</italic> = 14.6, 1.9 Hz, 2H), 4.28 (s, 2H), 4.09 (dd, <italic toggle="yes">J</italic> = 14.3, 7.1 Hz, 1H), 3.97&#8211;3.90 (m, 1H), 3.61 (dd, <italic toggle="yes">J</italic> = 15.2, 9.7 Hz, 1H), 3.29&#8211;3.20 (m, 2H), 3.17 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H), 2.99&#8211;2.87 (m, 2H), 2.87&#8211;2.75
(m, 1H), 2.75&#8211;2.54 (m, 3H), 2.26 (dd, <italic toggle="yes">J</italic> =
15.6, 7.5 Hz, 1H), 2.19&#8211;2.06 (m, 2H), 2.04&#8211;0.61 (m,
34H) ppm; <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#948; 173.4,
154.0, 149.6, 148.3, 145.1, 140.7, 140.0, 137.7, 135.9, 133.9, 130.3,
129.3, 127.0, 125.8, 125.4, 122.9, 119.9, 117.9, 117.8, 117.5, 115.0,
97.4, 83.1, 80.2, 79.1, 68.4, 68.2, 67.6, 66.9, 60.3, 59.5, 49.8,
49.1, 45.6, 41.2, 39.8, 39.0, 36.6, 35.7, 35.4, 34.0, 31.2, 27.9,
27.8, 27.4, 26.3, 22.8, 19.8, 18.6, 17.4, 14.4, 14.1, 12.5, 11.8 ppm;
ESI-MS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: [M + H]<sup>+</sup> Calcd
for C<sub>54</sub>H<sub>71</sub>N<sub>2</sub>O<sub>10</sub>
<sup>+</sup> 908; Found 908.</p></sec><sec id="sec4.5.4"><label>4.5.4</label><title>Ivermectin&#8211;Cinchonidine Conjugate <bold>7</bold>
</title><p>88 mg, 17% yield (over two steps). Isolated as
a white amorphous solid, a single spot by TLC. UV-active and strains
green with PMA; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#948;
8.89 (d, <italic toggle="yes">J</italic> = 4.5 Hz, 1H), 8.18 (d, <italic toggle="yes">J</italic> = 8.3 Hz, 1H), 8.13 (dd, <italic toggle="yes">J</italic> = 8.5, 0.9 Hz, 1H),
7.71 (ddd, <italic toggle="yes">J</italic> = 8.3, 6.9, 1.2 Hz, 1H), 7.59 (ddd, <italic toggle="yes">J</italic> = 8.3, 6.9, 1.2 Hz, 1H), 7.44 (d, <italic toggle="yes">J</italic> =
4.5 Hz, 1H), 6.37 (d, <italic toggle="yes">J</italic> = 6.5 Hz, 1H), 5.89&#8211;5.63
(m, 5H), 5.41 (s, 1H), 5.36&#8211;5.27 (m, 1H), 5.16&#8211;5.10
(m, 1H), 5.02&#8211;4.94 (m, 2H), 4.86 (s, 1H), 4.65 (qd, <italic toggle="yes">J</italic> = 14.5, 2.3 Hz, 2H), 4.28 (s, 2H), 4.10 (dd, <italic toggle="yes">J</italic> = 14.3, 7.1 Hz, 1H), 3.95 (d, <italic toggle="yes">J</italic> = 6.1 Hz, 1H),
3.71&#8211;3.62 (m, 1H), 3.34 (dd, <italic toggle="yes">J</italic> = 15.5, 7.3
Hz, 1H), 3.26 (dd, <italic toggle="yes">J</italic> = 4.5, 2.2 Hz, 1H), 3.19 (d, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 3.12 (s, 1H), 3.02 (dd, <italic toggle="yes">J</italic> = 13.8, 10.1 Hz, 1H), 2.70&#8211;2.53 (m, 4H), 2.33&#8211;2.22
(m, 3H), 2.08&#8211;0.69 (m, 33H) ppm; <sup>13</sup>C NMR (101 MHz,
CDCl<sub>3</sub>) &#948; 173.4, 154.1, 149.8, 148.4, 144.9, 141.4,
140.7, 137.7, 136.0, 134.3, 130.3, 129.3, 126.9, 125.7, 125.4, 123.0,
119.9, 118.1, 118.0, 117.7, 114.6, 97.4, 83.0, 80.2, 79.2, 77.9, 68.4,
68.2, 67.6, 67.0, 60.3, 59.7, 56.6, 45.6, 42.5, 41.2, 39.6, 39.0,
36.7, 35.7, 35.4, 34.2, 31.2, 28.0, 27.6, 27.4, 23.9, 19.8, 18.4,
17.4, 14.5, 14.1, 12.5, 11.8 ppm; ESI-MS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: [M + H]<sup>+</sup> Calcd for C<sub>54</sub>H<sub>71</sub>N<sub>2</sub>O<sub>10</sub>
<sup>+</sup> 908; Found 908.</p></sec><sec id="sec4.5.5"><label>4.5.5</label><title>Ivermectin&#8211;<italic toggle="yes">N</italic>-Deacetylthiocolchicine
Conjugate <bold>8</bold>
</title><p>79 mg, 14% yield (over two steps).
Isolated as a yellow, amorphous solid, a single spot by TLC. UV-active
and strains green with PMA; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#948; 7.65 (s, 1H), 7.19 (dd, <italic toggle="yes">J</italic> = 38.4, 10.5
Hz, 2H), 7.05 (s, 1H), 6.54 (s, 1H), 5.68&#8211;5.57 (m, 1H), 5.47&#8211;5.35
(m, 2H), 5.27&#8211;5.17 (m, 1H), 5.03 (d, <italic toggle="yes">J</italic> = 9.7
Hz, 1H), 4.78&#8211;4.50 (m, 3H), 4.28 (d, <italic toggle="yes">J</italic> = 5.4
Hz, 1H), 3.97 (d, <italic toggle="yes">J</italic> = 6.1 Hz, 1H), 3.89 (d, <italic toggle="yes">J</italic> = 3.8 Hz, 3H), 3.75&#8211;3.60 (m, 2H), 3.50 (s, 2H),
3.28&#8211;3.20 (m, 1H), 2.62&#8211;0.69 (m, 48H) ppm; <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#948; 182.2, 173.0, 158.5, 155.0,
153.5, 151.0, 151.0, 141.4, 139.5, 138.0, 137.7, 137.3, 135.2, 134.7,
134.3, 129.1, 126.9, 125.6, 124.6, 120.4, 118.2, 117.3, 107.4, 97.4,
80.5, 79.3, 79.2, 76.0, 68.7, 68.2, 67.6, 67.1, 61.4, 61.3, 56.1,
53.4, 45.5, 41.3, 38.9, 37.5, 36.5, 35.7, 35.3, 34.0, 31.1, 30.0,
29.6, 28.1, 27.4, 19.9, 19.2, 17.4, 15.1, 14.4, 12.5, 12.4 ppm; ESI-MS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: [M + H]<sup>+</sup> Calcd for C<sub>55</sub>H<sub>72</sub>NO<sub>13</sub>S<sup>+</sup> 986; Found 987;
[M + Na]<sup>+</sup> Calcd for C<sub>55</sub>H<sub>71</sub>NNaO<sub>13</sub>S<sup>+</sup> 1008; Found 1009.</p></sec></sec><sec id="sec4.6"><label>4.6</label><title>Synthesis of IVR Aglycon-1H-imidazole-1-carboxylate
(Compound <bold>9</bold>)</title><p>To a suspension of CDI (148 mg,
0.91 mmol, 2 equiv) in dry toluene (10 mL) was added dropwise a solution
of compound <bold>3</bold> (320 mg, 0.46 mmol, 1 equiv) in dry toluene
(5 mL). The resulting mixture was stirred at room temperature for
24 h. Thereafter, the reaction mixture was concentrated to dryness
by using a rotary evaporator, dissolved in CH<sub>2</sub>Cl<sub>2</sub>, and extracted with brine. The organic layers were then concentrated
under reduced pressure. The product was purified on silica gel using
the CombiFlash system (0% &#8594; 10% EtOAc/CHCl<sub>3</sub>), yielding
pure product <bold>9</bold> as an oil. After two evaporation steps
with <italic toggle="yes">n</italic>-pentane to remove any remaining solvent, the
oily product was fully converted to a yellow amorphous solid (215
mg, 59% yield). The spectroscopic data were in agreement with previously
published data.<xref rid="ref16" ref-type="bibr"/>
</p></sec><sec id="sec4.7"><label>4.7</label><title>General Procedure for the Preparation of Ivermectin
Conjugates with Nucleosides and Metronidazole (Compounds <bold>10&#8211;12</bold>)</title><p>The appropriate conjugation partner (nucleoside analog
or metronidazole, 1.5 equiv) was dissolved in DMF (20 mL), and after
being heated to 90 &#176;C, DBU (1.5 equiv) was added. After 30 min,
a solution of <bold>9</bold> (1.0 g, 1.26 mmol, 1 equiv) in DMF (20
mL) was added dropwise to the reaction mixture, and stirring was continued
for 24 h. Then, the reaction mixture was concentrated to dryness by
using a rotary evaporator, diluted with CH<sub>2</sub>Cl<sub>2</sub>, and extracted with brine. The collected organic layers were subsequently
concentrated <italic toggle="yes">in vacuo</italic>. Purification on silica gel
using the CombiFlash system (0% &#8594; 100% EtOAc/CHCl<sub>3</sub>) gave the respective C5-protected bioconjugates as clear oils.</p><p>To remove the C5-protecting group, the individual hybrids were dissolved
in methanol (10 mL), and <italic toggle="yes">para</italic>-toluenesulfonic acid
hydrate (80 mg, 0.46 mmol, 1.3 equiv) was added. After 2 h, the organic
solvent was evaporated, diluted with CH<sub>2</sub>Cl<sub>2</sub>,
and extracted with an aqueous solution of sodium carbonate (0.1 M).
Next, the collected organic layers were subsequently concentrated <italic toggle="yes">in vacuo</italic>. Purification on silica gel using the CombiFlash
system (0% &#8594; 100% EtOAc/CHCl<sub>3</sub>) gave the pure products <bold>10&#8211;12</bold> as clear oils. After twice the evaporation to
dryness with <italic toggle="yes">n</italic>-pentane, the oily products were completely
converted into white amorphous solids.</p><sec id="sec4.7.1"><label>4.7.1</label><title>Ivermectin&#8211;Floxuridine Conjugate <bold>10</bold>
</title><p>162 mg, 15% yield (over two steps). Isolated as
a white amorphous solid, a single spot by TLC. UV-active and strains
green with PMA; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#948;
9.83 (s, 1H), 7.73 (d, <italic toggle="yes">J</italic> = 6.1 Hz, 1H), 6.27 (t, <italic toggle="yes">J</italic> = 6.0 Hz, 1H), 6.18&#8211;6.10 (m, 2H), 5.70 (ddd, <italic toggle="yes">J</italic> = 24.3, 14.9, 10.1 Hz, 2H), 5.30 (td, <italic toggle="yes">J</italic> = 10.6, 5.5 Hz, 1H), 5.09 (d, <italic toggle="yes">J</italic> = 9.8 Hz, 1H),
4.98 (s, 1H), 4.62&#8211;4.33 (m, 5H), 4.21 (d, <italic toggle="yes">J</italic> = 3.3 Hz, 1H), 4.05 (d, <italic toggle="yes">J</italic> = 1.6 Hz, 1H), 3.73&#8211;3.64
(m, 1H), 3.59 (d, <italic toggle="yes">J</italic> = 9.1 Hz, 1H), 3.17 (d, <italic toggle="yes">J</italic> = 8.1 Hz, 1H), 2.66&#8211;2.58 (m, 2H), 2.55&#8211;2.46
(m, 2H), 2.37&#8211;0.57 (m, 35H) ppm; <sup>13</sup>C NMR (101 MHz,
CDCl<sub>3</sub>) &#948; 168.3, 156.9, 156.6, 154.6, 148.9, 141.9,
140.0, 139.5, 138.6, 135.7, 133.5, 129.6, 126.5, 122.4, 118.1, 97.3,
85.8, 84.5, 83.6, 83.0, 78.5, 77.2, 72.1, 71.0, 68.7, 68.1, 66.9,
40.5, 39.1, 36.7, 35.8, 35.5, 34.4, 33.1, 31.2, 29.7, 28.0, 27.2,
18.7, 17.4, 16.8, 14.5, 12.5, 11.7 ppm; ESI-MS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: [M + Na]<sup>+</sup> Calcd for C<sub>44</sub>H<sub>59</sub>FN<sub>2</sub>NaO<sub>14</sub>
<sup>+</sup> 881; Found 881.</p></sec><sec id="sec4.7.2"><label>4.7.2</label><title>Ivermectin&#8211;Azidothymidine Conjugate <bold>11</bold>
</title><p>321 mg, 29% yield (over two steps). Isolated as
a white amorphous solid, a single spot by TLC. UV-active and strains
green with PMA; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#948;
9.55 (s, 1H), 7.27 (d, <italic toggle="yes">J</italic> = 0.8 Hz, 1H), 6.15&#8211;6.05
(m, 2H), 5.67 (ddd, <italic toggle="yes">J</italic> = 24.7, 14.8, 10.6 Hz, 3H),
5.29&#8211;5.20 (m, 1H), 5.05 (d, <italic toggle="yes">J</italic> = 8.2 Hz, 1H),
4.96 (s, 1H), 4.84 (s, 1H), 4.53 (dd, <italic toggle="yes">J</italic> = 30.0, 14.4
Hz, 2H), 4.39 (ddd, <italic toggle="yes">J</italic> = 15.4, 12.0, 4.2 Hz, 2H),
4.22 (dd, <italic toggle="yes">J</italic> = 12.3, 5.2 Hz, 1H), 4.10&#8211;4.01
(m, 2H), 3.68&#8211;3.59 (m, 1H), 3.58&#8211;3.52 (m, 1H), 3.13
(d, <italic toggle="yes">J</italic> = 7.7 Hz, 1H), 2.79 (d, <italic toggle="yes">J</italic> =
6.5 Hz, 1H), 2.64&#8211;2.55 (m, 1H), 2.53&#8211;2.41 (m, 2H), 2.41&#8211;2.30
(m, 1H), 2.30&#8211;2.15 (m, 2H), 2.04&#8211;0.55 (m, 33H) ppm; <sup>13</sup>C NMR (101 MHz, <sub>CDCl3</sub>) &#948; 168.3, 163.6, 154.3,
150.2, 140.1, 138.8, 135.4, 133.6, 129.5, 126.5, 122.2, 117.8, 111.3,
97.2, 85.6, 83.6, 83.0, 81.6, 78.3, 77.1, 71.9, 68.5, 68.0, 66.8,
66.7, 60.4, 40.3, 38.9, 37.4, 36.6, 35.7, 35.4, 34.4, 33.1, 31.1,
29.6, 27.8, 27.2, 18.6, 17.3, 16.8, 14.4, 12.6, 12.4, 11.6 ppm; ESI-MS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: [M + Na]<sup>+</sup> Calcd for C<sub>45</sub>H<sub>61</sub>N<sub>5</sub>NaO<sub>13</sub>
<sup>+</sup> 902;
Found 902.</p></sec><sec id="sec4.7.3"><label>4.7.3</label><title>Ivermectin&#8211;Metronidazole Conjugate <bold>12</bold>
</title><p>296 mg, 30% yield (over two steps). Isolated as
a white amorphous solid, a single spot by TLC. UV-active and strains
green with PMA; <sup>1</sup>H NMR (401 MHz, CDCl<sub>3</sub>) &#948;
7.88 (s, 1H), 6.07 (dd, <italic toggle="yes">J</italic> = 7.2, 2.2 Hz, 2H), 5.61
(ddd, <italic toggle="yes">J</italic> = 24.8, 15.0, 10.3 Hz, 2H), 5.25&#8211;5.16
(m, 1H), 4.91 (d, <italic toggle="yes">J</italic> = 10.8 Hz, 1H), 4.81 (s, 1H),
4.79 (d, <italic toggle="yes">J</italic> = 15.5 Hz, 1H), 4.59&#8211;4.49 (m, 4H),
4.45 (dd, <italic toggle="yes">J</italic> = 12.2, 2.0 Hz, 2H), 4.37 (ddd, <italic toggle="yes">J</italic> = 11.3, 10.5, 5.4 Hz, 2H), 3.95 (d, <italic toggle="yes">J</italic> = 2.1 Hz, 1H), 3.64&#8211;3.56 (m, 1H), 3.50 (dd, <italic toggle="yes">J</italic> = 9.4, 2.0 Hz, 1H), 3.38 (s, 1H), 3.11 (d, <italic toggle="yes">J</italic> =
7.7 Hz, 1H), 2.57&#8211;0.51 (m, 35H) ppm; <sup>13</sup>C NMR (101
MHz, CDCl<sub>3</sub>) &#948; 168.5, 154.2, 150.8, 140.3, 138.6,
135.6, 133.5, 133.0, 129.6, 126.4, 122.2, 117.9, 97.2, 83.6, 82.9,
78.4, 77.2, 72.0, 68.6, 68.0, 66.8, 65.7, 45.2, 40.4, 38.9, 36.7,
35.8, 35.4, 34.4, 33.1, 31.2, 27.9, 27.3, 18.5, 17.3, 16.8, 14.4,
14.3, 12.4, 11.6 ppm; ESI-MS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: [M + Na]<sup>+</sup> Calcd for C<sub>41</sub>H<sub>57</sub>N<sub>3</sub>NaO<sub>12</sub>
<sup>+</sup> 806; Found 806.</p></sec></sec><sec id="sec4.8"><label>4.8</label><title>Synthesis of Betulinic Acid Propargyl Ester</title><p>A mixture of betulinic acid (2.0 g, 4.39 mmol, 1.0 equiv), DBU
(1.0 g, 6.58 mmol, 1.5 equiv), and propargyl bromide (1.57 g, 13.16
mmol, 3.0 equiv) in anhydrous toluene (50 mL) was heated at 90 &#176;C
for 24 h. Subsequently, the mixture was concentrated under reduced
pressure. Purification on silica gel using the CombiFlash system (0
&#8594; 50% EtOAc/<italic toggle="yes">n</italic>-hexane) yielded the pure product
of the reaction (62% yield) as a clear oil. The oil was then diluted
in <italic toggle="yes">n</italic>-pentane and evaporated to dryness three times
to yield an amorphous solid. The spectroscopic data were in agreement
with previously published data.<xref rid="ref36" ref-type="bibr"/>
</p></sec><sec id="sec4.9"><label>4.9</label><title>Synthesis of Artesunate Propargyl Ester</title><p>To a stirred solution of artesunate (1.0 g, 2.60 mmol, 1.0 equiv)
in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (40 mL) were added DCC (1.07
g, 5.20 mmol, 2.0 equiv) and a catalytic amount of DMAP. After 30
min, propargyl alcohol (730 mg, 13.02 mmol, 5 equiv) was added dropwise,
and stirring was continued for 24 h. The formation of a white precipitate
of DCU was observed. Afterward, the white precipitate was filtered
off, and the reaction mixture was concentrated to dryness using a
rotary evaporator. The product was then purified on silica gel using
the CombiFlash system (0% &#8594; 100% EtOAc/CHCl<sub>3</sub>), yielding
the pure product of the reaction (47% yield) as a clear oil. The oil
was then diluted in <italic toggle="yes">n</italic>-pentane and evaporated to dryness
three times to yield an amorphous solid. The spectroscopic data were
in agreement with previously published data.<xref rid="ref37" ref-type="bibr"/>
</p></sec><sec id="sec4.10"><label>4.10</label><title>Synthesis of Ivermectin C13-Chloroacetyl
Ester (Compound <bold>13</bold>)</title><p>Precursor <bold>3</bold> (1.0 g, 1.43 mmol, 1.0 equiv) was dissolved in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (30 mL). The solution was then cooled in an
ice bath, and pyridine (564 mg, 7.13 mmol, 5.0 equiv) was added. Next,
chloroacetyl chloride (322 mg, 2.85 mmol, 2.0 equiv) was added dropwise
to the reaction mixture. The solution turned brown, and stirring was
continued for 24 h. Thereafter, the reaction mixture was concentrated
to dryness using a rotary evaporator, diluted with CH<sub>2</sub>Cl<sub>2</sub>, and extracted with an aqueous solution of sulfuric acid
(pH = 1) and then with water. The collected organic layers were subsequently
concentrated <italic toggle="yes">in vacuo</italic>. Purification on silica gel
using the CombiFlash system (0% &#8594; 10% EtOAc/CHCl<sub>3</sub>) gave the respective product of the reaction (72% yield) as a clear
oil. The oil was then diluted in <italic toggle="yes">n</italic>-pentane and evaporated
to dryness three times to yield an amorphous solid. The spectroscopic
data were in agreement with the previously published data.<xref rid="ref15" ref-type="bibr"/>
</p></sec><sec id="sec4.11"><label>4.11</label><title>Synthesis of Ivermectin C13-Azide Precursor
(Compound <bold>14</bold>)</title><p>Ivermectin C13-chloroacetyl ester <bold>13</bold> (400 mg, 0.51 mmol, 1.0 equiv) was dissolved in DMF (10
mL). Sodium azide (67 mg, 1.02 mmol, 2.0 equiv) was then added in
one portion, the mixture was heated to 60 &#176;C, and stirring was
continued for 24 h. Afterward, the reaction mixture was diluted with
a large amount of water, and extracted several times with methylene
chloride. This step can be hazardous due to the potential for an explosion
resulting from the reaction between sodium azide and the chlorinated
solvent, so it is essential to follow the sequence of operations precisely.
The collected organic layers were subsequently concentrated <italic toggle="yes">in vacuo</italic>. This raw mixture was used directly in the next
step.</p></sec><sec id="sec4.12"><label>4.12</label><title>Synthesis of Ivermectin-Betulinic Acid Conjugate
(Compound <bold>15</bold>)</title><p>Under a nitrogen atmosphere, a
solution of <bold>14</bold> (&#8764;1.0 equiv) in anhydrous CH<sub>3</sub>CN was prepared. Betulinic acid propargyl ester (157 mg, 0.32
mmol, 1.0 equiv) and DIPEA (123 mg, 0.95 mmol, 3.0 equiv) were then
added, followed by the addition of catalytic CuI (6.05 mg, 0.03 mmol,
0.1 equiv) in one portion. The reaction mixture was stirred at room
temperature for 24 h. After complete consumption of the propargyl
partner (monitored by TLC and ESI-MS), the organic solvent was removed
by using a rotary evaporator. The oily residue was dissolved in a
small amount of CH<sub>2</sub>Cl<sub>2</sub> and extracted several
times with 10% aqueous EDTA solution. The organic phases were separated
and concentrated under reduced pressure. The product was purified
by silica gel chromatography using the CombiFlash system (0 &#8594;
100% EtOAc/CHCl<sub>3</sub>), yielding the pure product of the click
reaction as a clear oil. The oil was diluted in <italic toggle="yes">n</italic>-pentane and evaporated to dryness three times to obtain the amorphous
solid.</p><p>To remove the C5-protecting group, the hybrid was dissolved
in methanol (10 mL), and <italic toggle="yes">para</italic>-toluenesulfonic acid
hydrate (80 mg, 0.46 mmol, 1.3 equiv) was added. After 2 h, the organic
solvent was evaporated, diluted with CH<sub>2</sub>Cl<sub>2</sub>,
and extracted with an aqueous solution of sodium carbonate (0.1 M).
Next, the collected organic layers were subsequently concentrated <italic toggle="yes">in vacuo</italic>. Purification on silica gel using the CombiFlash
system (0% &#8594; 100% EtOAc/CHCl<sub>3</sub>) gave the pure product <bold>15</bold> as s clear oil. After twice evaporation to dryness with <italic toggle="yes">n</italic>-pentane, the oily product was completely converted into
a white amorphous solid.</p><sec id="sec4.12.1"><label>4.12.1</label><title>Ivermectin&#8211;Betulinic Acid Conjugate <bold>15</bold>
</title><p>122 mg, 33% yield (over two steps). Isolated as
a white amorphous solid, a single spot by TLC. UV-active and strains
green with PMA; <sup>1</sup>H NMR (401 MHz, CD<sub>2</sub>Cl<sub>2</sub>) &#948; 7.78 (s, 1H), 6.17 (d, <italic toggle="yes">J</italic> = 2.0 Hz, 1H),
6.12 (dt, <italic toggle="yes">J</italic> = 10.8, 2.4 Hz, 1H), 5.81 (ddd, <italic toggle="yes">J</italic> = 20.3, 10.5, 6.7 Hz, 1H), 5.72&#8211;5.62 (m, 1H), 5.32
(m, 1H), 5.30&#8211;5.25 (m, 3H), 5.22 (dd, <italic toggle="yes">J</italic> =
9.7, 3.6 Hz, 3H), 5.06&#8211;5.00 (m, 1H), 4.75 (s, 1H), 4.72 (d, <italic toggle="yes">J</italic> = 2.3 Hz, 1H), 4.58 (dd, <italic toggle="yes">J</italic> = 2.4, 1.4
Hz, 1H), 4.58&#8211;4.45 (m, 2H), 3.97 (d, <italic toggle="yes">J</italic> = 2.2
Hz, 1H), 3.76&#8211;3.67 (m, 1H), 3.55&#8211;3.47 (m, 1H), 3.24
(dd, <italic toggle="yes">J</italic> = 9.9, 5.1 Hz, 1H), 3.13 (dd, <italic toggle="yes">J</italic> = 12.1, 4.0 Hz, 1H), 3.02&#8211;2.95 (m, 1H), 2.73&#8211;2.62
(m, 1H), 2.53&#8211;0.62 (m, 76H) ppm; <sup>13</sup>C NMR (101 MHz,
CD<sub>2</sub>Cl<sub>2</sub>) &#948; 176.3, 169.2, 166.2, 151.3,
144.2, 141.2, 139.3, 136.2, 134.0, 130.4, 127.2, 125.8, 122.7, 118.7,
109.9, 97.9, 83.7, 81.6, 79.2, 79.0, 77.7, 72.7, 69.3, 68.7, 67.5,
57.6, 57.0, 55.8, 51.2, 51.1, 50.0, 47.6, 42.9, 41.3, 41.0, 39.5,
39.3, 39.3, 38.8, 37.7, 37.4, 36.4, 36.1, 35.0, 34.8, 33.9, 32.5,
31.8, 31.1, 30.1, 28.5, 28.3, 28.0, 28.0, 26.1, 21.4, 19.6, 19.2,
18.8, 17.8, 17.2, 16.5, 16.1, 15.8, 15.0, 14.9, 13.0, 12.1 ppm; ESI-MS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: [M + Na]<sup>+</sup> Calcd for C<sub>69</sub>H<sub>101</sub>N<sub>3</sub>NaO<sub>12</sub>
<sup>+</sup> 1187;
Found 1188.</p></sec></sec><sec id="sec4.13"><label>4.13</label><title>Synthesis of Ivermectin-Artesunate Conjugate
(Compound <bold>16</bold>)</title><p>To remove the C5-protecting group,
azide <bold>14</bold> was dissolved in methanol (10 mL), and <italic toggle="yes">para</italic>-toluenesulfonic acid hydrate (80 mg, 0.46 mmol, 1.3
equiv) was added. After 2 h, the organic solvent was evaporated, diluted
with CH<sub>2</sub>Cl<sub>2</sub>, and extracted with an aqueous solution
of sodium carbonate (0.1 M). Next, the collected organic layers were
subsequently concentrated <italic toggle="yes">in vacuo</italic>. This raw mixture
was used directly in the next step.</p><p>Under a nitrogen atmosphere,
a solution of deprotected azide (&#8764;1.0 equiv) in anhydrous CH<sub>3</sub>CN was prepared. Artesunate propargyl ester (135 mg, 0.32
mmol, 1.0 equiv) and DIPEA (123 mg, 0.95 mmol, 3.0 equiv) were then
added, followed by the addition of catalytic CuI (6.05 mg, 0.03 mmol,
0.1 equiv) in one portion. The reaction mixture was stirred at room
temperature for 24 h. After complete consumption of the propargyl
partner (monitored by TLC and ESI-MS), the organic solvent was removed
using a rotary evaporator. The oily residue was dissolved in a small
amount of CH<sub>2</sub>Cl<sub>2</sub> and extracted several times
with 10% aqueous EDTA solution. The organic phases were separated
and concentrated under reduced pressure. The product was purified
by silica gel chromatography using the CombiFlash system (0 &#8594;
100% EtOAc/CHCl<sub>3</sub>), yielding the pure product <bold>16</bold> of the click reaction as a clear oil. The oil was diluted in <italic toggle="yes">n</italic>-pentane and evaporated to dryness three times to obtain
the amorphous solid.</p><sec id="sec4.13.1"><label>4.13.1</label><title>Ivermectin&#8211;Artesunate Conjugate <bold>16</bold>
</title><p>220 mg, 63% yield (yield of one step&#8211;click
reaction). Isolated as a white amorphous solid, a single spot by TLC.
UV-active and strains green with PMA; <sup>1</sup>H NMR (401 MHz,
CDCl<sub>3</sub>) &#948; 7.80 (s, 1H), 6.18&#8211;6.13 (m, 2H),
5.75 (dt, <italic toggle="yes">J</italic> = 11.0, 8.0 Hz, 2H), 5.62 (dd, <italic toggle="yes">J</italic> = 15.0, 10.0 Hz, 1H), 5.42 (s, 1H), 5.35&#8211;5.26 (m,
5H), 5.21 (s, 1H), 4.94 (d, <italic toggle="yes">J</italic> = 11.2 Hz, 1H), 4.83
(s, 1H), 4.53 (qd, <italic toggle="yes">J</italic> = 14.1, 2.2 Hz, 2H), 4.04 (d, <italic toggle="yes">J</italic> = 2.2 Hz, 1H), 3.74&#8211;3.65 (m, 1H), 3.61&#8211;3.55
(m, 1H), 3.20 (d, <italic toggle="yes">J</italic> = 7.8 Hz, 1H), 2.78&#8211;0.61
(m, 60H) ppm; <sup>13</sup>C NMR (101 MHz, CDCl<sup>3</sup>) &#948;
171.8, 170.9, 168.6, 165.3, 143.2, 140.5, 138.7, 135.5, 133.4, 129.6,
126.5, 125.2, 122.2, 118.1, 104.4, 97.3, 92.1, 91.4, 82.8, 81.0, 80.0,
78.4, 72.1, 68.7, 68.1, 66.8, 57.9, 51.5, 50.5, 45.1, 40.4, 38.8,
37.2, 36.7, 36.1, 35.8, 35.4, 34.4, 34.0, 33.2, 31.7, 31.2, 29.6,
29.1, 28.7, 27.9, 27.4, 25.8, 24.5, 21.9, 20.1, 18.8, 17.4, 16.8,
14.5, 12.6, 11.9, 11.7 ppm; ESI-MS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: [M + Na]<sup>+</sup> Calcd for C<sub>58</sub>H<sub>81</sub>N<sub>3</sub>NaO<sub>17</sub>
<sup>+</sup> 1115; Found 1114.</p></sec></sec><sec id="sec4.14"><label>4.14</label><title>In Vitro Biological Studies</title><sec id="sec4.14.1"><label>4.14.1</label><title>Trypanocidal and Cytotoxic Assays</title><p>The 427&#8211;221a clone of bloodstream forms of <xref rid="ref38" ref-type="bibr"/> and human
promyelocytic leukemia HL-60 cells<xref rid="ref39" ref-type="bibr"/> were
used for evaluating the trypanocidal and cytotoxic activity of test
compounds. Trypanosomes and HL-cells were seeded in 96-well plates
at cell densities of 1 &#215; 10<sup>&#8211;4</sup> and 5 &#215;
10<sup>&#8211;4</sup> mL<sup>&#8211;1</sup>, respectively, in 200
&#956;L of Baltz medium<xref rid="ref40" ref-type="bibr"/> supplemented
with 16.7% bovine serum. Test compounds were assayed at 10-fold dilutions
ranging from 100 &#956;M to 1 nM in the presence of 0.9% DMSO. Controls
were grown in the culture medium containing only 0.9% DMSO. The assays
were cultured in an incubator at 37 &#176;C in a humidified atmosphere
containing 5% CO<sub>2</sub>. After 24 h incubation, 20 &#956;L of
0.5 mM resazurin (prepared in sterile PBS) was added, and the cultures
were grown for another 48 h. Then, the proliferation of the cells
was determined by measuring the absorbance at 570 nm (test wavelength)
and 630 nm (reference wavelength) using a microplate reader. The half-maximal
growth inhibition (GI<sub>50</sub>) values, i.e., the concentration
of a test compound that reduces the growth rate of cells by 50% compared
to the growth rate of the control cells, were calculated using the
method described by Huber and Koella.<xref rid="ref41" ref-type="bibr"/>
</p></sec><sec id="sec4.14.2"><label>4.14.2</label><title>Human Cell Lines</title><p>The human cancer
cell lines PC3 (metastatic prostate cancer), MDA-MB-231 (breast cancer),
A549 (lung cancer), HCT-116 (colon carcinoma), and the immortalized
human keratinocyte line HaCaT were obtained from the repository of
the Medical University of Warsaw. PC3 cells were cultured in RPMI
(Biowest SAS, France) and HCT-116 cells in MEM (Thermo Scientific,
USA), while A549, MDA-MB-231, and HaCaT cells were maintained in DMEM
High Glucose (Biowest SAS, France). The culture media were enriched
with 10% fetal bovine serum (FBS, Sigma-Aldrich, St. Louis, MO, USA),
20 mM HEPES (Biowest, Nuaill&#233;, France), and antibiotics (100
U/mL penicillin and 100 &#956;g/mL streptomycin) obtained from Gibco
(Grand Island, NY, USA). The cells were maintained in a humidified
incubator at 37 &#176;C with 5% CO<sub>2</sub> until they reached
80&#8211;90% confluence, after which they were used for further experiments.</p></sec><sec id="sec4.14.3"><label>4.14.3</label><title>Cytotoxicity</title><p>To assess the cytotoxicity,
the cells (0.5 &#215; 10<sup>4</sup>/well) were plated in 96-well
plates and allowed to adhere for 24 h. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay was used to evaluate the cytotoxic effects of <bold>IVR</bold> bioconjugates on all tested cell lines. After 24 h incubation,
cells were exposed to varying concentrations (1 to 100 &#956;M) of
the test compounds for 72 h. Following the treatment, the medium was
discarded, and a 0.5 mg mL<sup>&#8211;1</sup> MTT solution was added
to each well and incubation was continued for another 4 h. Mitochondrial
enzyme activity facilitated the formation of formazan crystals, which
were subsequently dissolved in DMSO-isopropanol (1:1, v/v), producing
a violet-colored solution. A 100 &#956;L aliquot of this solution
was transferred to the well, and absorbance was recorded at 570 nm
using a MultiscanGo spectrophotometer (ThermoFisher Scientific, Carlsbad,
CA, USA).</p><p>Cytotoxicity was quantified by comparing the absorbance
of the treated cells to that of untreated controls using the formula:
[A]/[B] &#215; 100, where [A] represents the absorbance of the treated
sample and [B] corresponds to the absorbance of the control sample.
A decrease in MTT levels reflects a decrease in cell viability. IC<sub>50</sub> values, the concentration required to inhibit 50% of cell
viability, were calculated using GraphPad Prism 8.0.1 software.</p></sec></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao5c02998_si_001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ack1"><p>M.S. wishes to acknowledge
Adam Mickiewicz University
Foundation for a scholarship for the academic year 2024/2025.</p></ack><notes id="notes1" notes-type="data-availability"><p>The data underlying
this study are available in the published article and its Supporting
Information.</p></notes><notes id="notes2" notes-type="si"><p>The Supporting Information is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/10.1021/acsomega.5c02998?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acsomega.5c02998</ext-link>.<list list-type="simple" id="silist"><list-item><p>General procedures, as well as NMR and ESI-MS spectra
of the reported compounds (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.5c02998/suppl_file/ao5c02998_si_001.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item></list>
</p></notes><notes id="notes3" notes-type="author-contributions"><p>All authors
have given approval to the final version of the manuscript.</p></notes><notes id="notes4" notes-type="funding-statement"><p>The synthesis
of ivermectin derivatives was financially supported by a Diamond Grant
(0159/DIA/2020/49) funded by the Polish Ministry of Science and Higher
Education (MNiSW) to M.S.</p></notes><notes id="notes5" notes-type="conflict-of-interest"><p>The authors
declare no competing financial interest.</p></notes><glossary><def-list specific-use="delimiter-char:, " id="dl1"><title>Abbreviations</title><def-item><term>A549</term><def><p>lung
cancer cell line</p></def></def-item><def-item><term>CDI</term><def><p>1,1&#8217;-carbonyldiimidazole</p></def></def-item><def-item><term>CuAAC</term><def><p>copper-catalyzed
azide&#8211;alkyne cycloaddition</p></def></def-item><def-item><term>DBU</term><def><p>1,8-diazabicyklo&#173;[5.4.0]&#173;undek-7-en</p></def></def-item><def-item><term>DCC</term><def><p>
<italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>&#8242;-dicyclohexylcarbodiimide)</p></def></def-item><def-item><term>DIPEA</term><def><p>
<italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-diisopropylethylamine</p></def></def-item><def-item><term>DMAP</term><def><p>4-dimethylaminopyridine</p></def></def-item><def-item><term>DMF</term><def><p>
<italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-dimethylformamide</p></def></def-item><def-item><term>DNA</term><def><p>DNA</p></def></def-item><def-item><term>ESI-MS</term><def><p>electrospray
ionization mass spectrometry</p></def></def-item><def-item><term>GI50</term><def><p>half-maximal growth inhibition</p></def></def-item><def-item><term>HaCaT</term><def><p>human keratinocytes</p></def></def-item><def-item><term>HCT-116</term><def><p>primary colon cancer</p></def></def-item><def-item><term>HL-60</term><def><p>promyelocytic leukemia
cell line</p></def></def-item><def-item><term>IC50</term><def><p>half-maximal
inhibitory concentration</p></def></def-item><def-item><term>IVR</term><def><p>ivermectin</p></def></def-item><def-item><term>MDA-MB-231</term><def><p>triple-negative breast adenocarcinoma</p></def></def-item><def-item><term>MDR</term><def><p>multidrug resistance</p></def></def-item><def-item><term>MTT</term><def><p>3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide</p></def></def-item><def-item><term>NMR</term><def><p>nuclear
magnetic resonance</p></def></def-item><def-item><term>PC3</term><def><p>metastatic prostate cancer</p></def></def-item><def-item><term>pTsOH</term><def><p>para-toluenesulfonic acid</p></def></def-item><def-item><term>pyr</term><def><p>pyridine</p></def></def-item><def-item><term>ROS</term><def><p>reactive-oxygen species</p></def></def-item><def-item><term>rt</term><def><p>room temperature</p></def></def-item><def-item><term>SI</term><def><p>selectivity index</p></def></def-item><def-item><term>TBDMSCl</term><def><p>
<italic toggle="yes">tert</italic>-butyldimethylsilyl chloride</p></def></def-item><def-item><term>TEA</term><def><p>triethylamine</p></def></def-item><def-item><term>THF</term><def><p>tetryhydrofuran</p></def></def-item><def-item><term>WHO</term><def><p>World Health Organization</p></def></def-item></def-list></glossary><ref-list><ref id="ref1"><mixed-citation publication-type="weblink" id="cit1"><person-group person-group-type="allauthors"><collab>World Health Organization</collab></person-group>. <source>Cancer</source>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/fact-sheets/detail/cancer">https://www.who.int/news-room/fact-sheets/detail/cancer</uri>. (on-line access: 2025&#8211;04&#8211;02)</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="weblink" id="cit2"><person-group person-group-type="allauthors"><collab>Global Cancer Observatory</collab></person-group>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://gco.iarc.fr/">https://gco.iarc.fr/</uri>. (on-line access: 2025&#8211;04&#8211;02).</mixed-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Basak</surname><given-names>D.</given-names></name><name name-style="western"><surname>Arrighi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Darwiche</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deb</surname><given-names>S.</given-names></name><article-title>Comparison of Anticancer
Drug Toxicities: Paradigm Shift in Adverse Effect Profile</article-title><source>Life (Basel)</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>48</fpage><pub-id pub-id-type="doi">10.3390/life12010048</pub-id><pub-id pub-id-type="pmcid">PMC8777973</pub-id><pub-id pub-id-type="pmid">35054441</pub-id></element-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Zimmermann</surname><given-names>G. R.</given-names></name><name name-style="western"><surname>Leh&#225;r</surname><given-names>J.</given-names></name><name name-style="western"><surname>Keith</surname><given-names>C. T.</given-names></name><article-title>Multi-Target Therapeutics: When the
Whole Is Greater than the Sum of the Parts</article-title><source>Drug Discovery Today</source><year>2007</year><volume>12</volume><issue>1&#8211;2</issue><fpage>34</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2006.11.008</pub-id><pub-id pub-id-type="pmid">17198971</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Lutz</surname><given-names>J.-F.</given-names></name><name name-style="western"><surname>Zarafshani</surname><given-names>Z.</given-names></name><article-title>Efficient
Construction of Therapeutics, Bioconjugates,
Biomaterials and Bioactive Surfaces Using Azide&#8211;Alkyne &#8220;Click&#8221;
Chemistry</article-title><source>Adv. Drug Delivery Rev.</source><year>2008</year><volume>60</volume><issue>9</issue><fpage>958</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2008.02.004</pub-id><pub-id pub-id-type="pmid">18406491</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Crump</surname><given-names>A.</given-names></name><article-title>Ivermectin:
enigmatic multifaceted &#8217;wonder&#8217; drug continues to surprise
and exceed expectations</article-title><source>J. Antibiot (Tokyo)</source><year>2017</year><volume>70</volume><issue>5</issue><fpage>495</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1038/ja.2017.11</pub-id><pub-id pub-id-type="pmid">28196978</pub-id></element-citation></ref><ref id="ref7"><element-citation publication-type="journal" id="cit7"><name name-style="western"><surname>Campbell</surname><given-names>W.
C.</given-names></name><article-title>History
of Avermectin and Ivermectin, with Notes on the History of Other Macrocyclic
Lactone Antiparasitic Agents</article-title><source>Curr. Pharm. Biotechnol.</source><year>2012</year><volume>13</volume><issue>6</issue><fpage>853</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.2174/138920112800399095</pub-id><pub-id pub-id-type="pmid">22039784</pub-id></element-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Sulik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Antoszczak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huczy&#324;ski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Steverding</surname><given-names>D.</given-names></name><article-title>Antiparasitic
Activity of Ivermectin: Four Decades of Research into a &#8220;Wonder
Drug.&#8221;</article-title><source>Eur. J. Med. Chem.</source><year>2023</year><volume>261</volume><elocation-id>115838</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115838</pub-id><pub-id pub-id-type="pmid">37793327</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Markowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kaysiewicz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Markowska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huczy&#324;ski</surname><given-names>A.</given-names></name><article-title>Doxycycline,
Salinomycin, Monensin and Ivermectin Repositioned as Cancer Drugs</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2019</year><volume>29</volume><issue>13</issue><fpage>1549</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2019.04.045</pub-id><pub-id pub-id-type="pmid">31054863</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Crump</surname><given-names>A.</given-names></name><name name-style="western"><surname>O&#773;mura</surname><given-names>S.</given-names></name><article-title>Ivermectin,
&#8220;Wonder Drug&#8221; from Japan:
The Human Use Perspective</article-title><source>Proc. Jpn. Acad.
Ser. B</source><year>2011</year><volume>87</volume><issue>2</issue><fpage>13</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.2183/pjab.87.13</pub-id><pub-id pub-id-type="pmid">21321478</pub-id><pub-id pub-id-type="pmcid">PMC3043740</pub-id></element-citation></ref><ref id="ref11"><mixed-citation publication-type="weblink" id="cit11"><source>The 2015 Nobel Prize in Physiology or Medicine&#8211;Press
release</source>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nobelprize.org/prizes/medicine/2015/press-release/">https://www.nobelprize.org/prizes/medicine/2015/press-release/</uri>. [on-line access: 2025&#8211;04&#8211;02].</mixed-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name name-style="western"><surname>Juarez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schcolnik-Cabrera</surname><given-names>A.</given-names></name><name name-style="western"><surname>Due&#241;as-Gonzalez</surname><given-names>A.</given-names></name><article-title>The Multitargeted Drug
Ivermectin: From an Antiparasitic Agent to a Repositioned Cancer Drug</article-title><source>Am. J. Cancer Res.</source><year>2018</year><volume>8</volume><issue>2</issue><fpage>317</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">29511601</pub-id><pub-id pub-id-type="pmcid">PMC5835698</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Antoszczak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Markowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Markowska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huczy&#324;ski</surname><given-names>A.</given-names></name><article-title>Old Wine in
New Bottles: Drug Repurposing in Oncology</article-title><source>Eur.
J. Pharmacol.</source><year>2020</year><volume>866</volume><elocation-id>172784</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejphar.2019.172784</pub-id><pub-id pub-id-type="pmid">31730760</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Sulik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Otto-&#346;lusarczyk</surname><given-names>D.</given-names></name><name name-style="western"><surname>Antoszczak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Struga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huczy&#324;ski</surname><given-names>A.</given-names></name><article-title>Ivermectin and Its Synthetic Derivatives&#8211;A
New Class of Anticancer Agents</article-title><source>Eur. J. Med.
Chem. Rep.</source><year>2024</year><volume>12</volume><elocation-id>100176</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejmcr.2024.100176</pub-id></element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Singh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fontinha</surname><given-names>D.</given-names></name><name name-style="western"><surname>Francisco</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mendes</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Prud&#234;ncio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K.</given-names></name><article-title>Molecular Design and Synthesis of Ivermectin Hybrids Targeting Hepatic
and Erythrocytic Stages of Plasmodium Parasites</article-title><source>J. Med. Chem.</source><year>2020</year><volume>63</volume><issue>4</issue><fpage>1750</fpage><lpage>1762</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c00033</pub-id><pub-id pub-id-type="pmid">32011136</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Singh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fontinha</surname><given-names>D.</given-names></name><name name-style="western"><surname>Francisco</surname><given-names>D.</given-names></name><name name-style="western"><surname>Prud&#234;ncio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K.</given-names></name><article-title>Synthesis and Antiplasmodial Activity
of Regioisomers and Epimers
of Second-Generation Dual Acting Ivermectin Hybrids</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>564</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-04532-w</pub-id><pub-id pub-id-type="pmid">35022455</pub-id><pub-id pub-id-type="pmcid">PMC8755717</pub-id></element-citation></ref><ref id="ref17"><mixed-citation publication-type="book" id="cit17"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Kacprzak</surname>, <given-names>K. M.</given-names></string-name></person-group><article-title>Chemistry and
Biology of Cinchona Alkaloids</article-title>, in: <source>Natural
Products</source>; <publisher-name>Springer Berlin Heidelberg</publisher-name>: <publisher-loc>Berlin, Heidelberg</publisher-loc>, <year>2013</year>: <fpage>605</fpage>&#8211;<lpage>641</lpage>.</mixed-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Solary</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mannone</surname><given-names>L.</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>D.</given-names></name><name name-style="western"><surname>Caillot</surname><given-names>D.</given-names></name><name name-style="western"><surname>Casasnovas</surname><given-names>R.-O.</given-names></name><name name-style="western"><surname>Guy</surname><given-names>H.</given-names></name><name name-style="western"><surname>Grandjean</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>J.-E.</given-names></name><name name-style="western"><surname>Andr&#233;</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fenaux</surname><given-names>P.</given-names></name><name name-style="western"><surname>Canal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chauffert</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wotawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bayssas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Genne</surname><given-names>P.</given-names></name><article-title>Phase I Study of Cinchonine,
a Multidrug Resistance Reversing Agent, Combined with the CHVP Regimen
in Relapsed and Refractory Lymphoproliferative Syndromes</article-title><source>Leukemia</source><year>2000</year><volume>14</volume><issue>12</issue><fpage>2085</fpage><lpage>2094</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2401945</pub-id><pub-id pub-id-type="pmid">11187897</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Power</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>Kemeny</surname><given-names>N. E.</given-names></name><article-title>The Role of Floxuridine
in Metastatic Liver Disease</article-title><source>Mol. Cancer Ther.</source><year>2009</year><volume>8</volume><issue>5</issue><fpage>1015</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-08-0709</pub-id><pub-id pub-id-type="pmid">19383854</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Oates</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>A. J. J.</given-names></name><name name-style="western"><surname>Yarchoan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mitsuya</surname><given-names>H.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Broder</surname><given-names>S.</given-names></name><article-title>Clinical Pharmacology of 3&#8242;-Azido-2&#8217;,3&#8242;-Dideoxythymidine
(Zidovudine) and Related Dideoxynucleosides</article-title><source>N. Engl. J. Med.</source><year>1989</year><volume>321</volume><issue>11</issue><fpage>726</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1056/NEJM198909143211106</pub-id><pub-id pub-id-type="pmid">2671731</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Czerwonka</surname><given-names>D.</given-names></name><name name-style="western"><surname>Maj</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wietrzyk</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huczy&#324;ski</surname><given-names>A.</given-names></name><article-title>Synthesis of Thiocolchicine Amine
Derivatives and Evaluation of Their Antiproliferative Activity</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2021</year><volume>52</volume><elocation-id>128382</elocation-id><pub-id pub-id-type="doi">10.1016/j.bmcl.2021.128382</pub-id><pub-id pub-id-type="pmid">34592435</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Fulda</surname><given-names>S.</given-names></name><article-title>Betulinic
Acid for Cancer Treatment and Prevention</article-title><source>Int.
J. Mol. Sci.</source><year>2008</year><volume>9</volume><issue>6</issue><fpage>1096</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.3390/ijms9061096</pub-id><pub-id pub-id-type="pmid">19325847</pub-id><pub-id pub-id-type="pmcid">PMC2658785</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Wen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>B. C.-L.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>M.-H.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>P.-C.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>C.-K.</given-names></name><article-title>Artemisinin
and Its Derivatives as Potential Anticancer Agents</article-title><source>Molecules</source><year>2024</year><volume>29</volume><issue>16</issue><fpage>3886</fpage><pub-id pub-id-type="doi">10.3390/molecules29163886</pub-id><pub-id pub-id-type="pmid">39202965</pub-id><pub-id pub-id-type="pmcid">PMC11356986</pub-id></element-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24"><name name-style="western"><surname>Ruwizhi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Maseko</surname><given-names>R. B.</given-names></name><name name-style="western"><surname>Aderibigbe</surname><given-names>B. A.</given-names></name><article-title>Recent
Advances in the Therapeutic
Efficacy of Artesunate</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><issue>3</issue><fpage>504</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics14030504</pub-id><pub-id pub-id-type="pmid">35335880</pub-id><pub-id pub-id-type="pmcid">PMC8951414</pub-id></element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Patel</surname><given-names>O. P. S.</given-names></name><name name-style="western"><surname>Jesumoroti</surname><given-names>O. J.</given-names></name><name name-style="western"><surname>Legoabe</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Beteck</surname><given-names>R. M.</given-names></name><article-title>Metronidazole-Conjugates:
A Comprehensive Review of Recent Developments towards Synthesis and
Medicinal Perspective</article-title><source>Eur. J. Med. Chem.</source><year>2021</year><volume>210</volume><elocation-id>112994</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112994</pub-id><pub-id pub-id-type="pmid">33234343</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Malvy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chappuis</surname><given-names>F.</given-names></name><article-title>Sleeping Sickness</article-title><source>Clin. Microbiol.
Infect.</source><year>2011</year><volume>17</volume><issue>7</issue><fpage>986</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2011.03536.x</pub-id><pub-id pub-id-type="pmid">21722252</pub-id></element-citation></ref><ref id="ref27"><mixed-citation publication-type="book" id="cit27"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Steverding</surname>, <given-names>D.</given-names></string-name></person-group><article-title>Sleeping
Sickness and Nagana Disease Caused by Trypanosoma brucei</article-title>, in: <source>Arthropod Borne Diseases</source>; <publisher-name>Springer International Publishing</publisher-name>: <publisher-loc>Cham</publisher-loc>, <year>2017</year>: <fpage>277</fpage>&#8211;<lpage>297</lpage>.</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="weblink" id="cit28"><person-group person-group-type="allauthors"><collab>World Health Organization</collab></person-group>&#8211;<source>Trypanosomiasis, Human African (Sleeping
Sickness)</source>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-(sleeping-sickness)">https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-(sleeping-sickness)</uri>. [on-line access: 2025&#8211;04&#8211;02].</mixed-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name name-style="western"><surname>Sulik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fontinha</surname><given-names>D.</given-names></name><name name-style="western"><surname>Steverding</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sobczak</surname><given-names>S.</given-names></name><name name-style="western"><surname>Antoszczak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prud&#234;ncio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huczy&#324;ski</surname><given-names>A.</given-names></name><article-title>Unexpected Rearrangement of Ivermectin
in the Synthesis of New Derivatives with Trypanocidal and Antiplasmodial
Activities</article-title><source>Eur. J. Med. Chem.</source><year>2024</year><volume>263</volume><elocation-id>115951</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115951</pub-id><pub-id pub-id-type="pmid">37988797</pub-id></element-citation></ref><ref id="ref30"><mixed-citation publication-type="weblink" id="cit30"><person-group person-group-type="allauthors"><collab>World
Health Organization</collab></person-group>. <source>Ending the neglect
to attain the sustainable
development goals: a road map for neglected tropical diseases 2021&#8211;2030</source>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/i/item/9789240010352">https://www.who.int/publications/i/item/9789240010352</uri>. [on-line
access: 2025&#8211;04&#8211;02].</mixed-citation></ref><ref id="ref31"><element-citation publication-type="journal" id="cit31"><name name-style="western"><surname>Baker</surname><given-names>N.</given-names></name><name name-style="western"><surname>de Koning</surname><given-names>H. P.</given-names></name><name name-style="western"><surname>M&#228;ser</surname><given-names>P.</given-names></name><name name-style="western"><surname>Horn</surname><given-names>D.</given-names></name><article-title>Drug Resistance in
African Trypanosomiasis: The Melarsoprol and Pentamidine Story</article-title><source>Trends Parasitol.</source><year>2013</year><volume>29</volume><issue>3</issue><fpage>110</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2012.12.005</pub-id><pub-id pub-id-type="pmid">23375541</pub-id><pub-id pub-id-type="pmcid">PMC3831158</pub-id></element-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Weymouth-Wilson</surname><given-names>A. C.</given-names></name><article-title>The Role
of Carbohydrates in Biologically Active Natural Products</article-title><source>Nat. Prod. Rep.</source><year>1997</year><volume>14</volume><issue>2</issue><fpage>99</fpage><pub-id pub-id-type="doi">10.1039/np9971400099</pub-id><pub-id pub-id-type="pmid">9149408</pub-id></element-citation></ref><ref id="ref33"><element-citation publication-type="journal" id="cit33"><name name-style="western"><surname>Mrozik</surname><given-names>H.</given-names></name><name name-style="western"><surname>Linn</surname><given-names>B. O.</given-names></name><name name-style="western"><surname>Eskola</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lusi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matzuk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Preiser</surname><given-names>F. A.</given-names></name><name name-style="western"><surname>Ostlind</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Schaeffer</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>M. H.</given-names></name><article-title>Syntheses and Biological Activities of 13-Substituted
Avermectin Aglycons</article-title><source>J. Med. Chem.</source><year>1989</year><volume>32</volume><issue>2</issue><fpage>375</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1021/jm00122a015</pub-id><pub-id pub-id-type="pmid">2913297</pub-id></element-citation></ref><ref id="ref34"><element-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Meldal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diness</surname><given-names>F.</given-names></name><article-title>Recent Fascinating
Aspects of the CuAAC Click Reaction</article-title><source>Trends
Chem.</source><year>2020</year><volume>2</volume><issue>6</issue><fpage>569</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1016/j.trechm.2020.03.007</pub-id></element-citation></ref><ref id="ref35"><element-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Antoszczak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Urbaniak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Delgado</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maj</surname><given-names>E.</given-names></name><name name-style="western"><surname>Borgstr&#246;m</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wietrzyk</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huczy&#324;ski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Strand</surname><given-names>D.</given-names></name><article-title>Biological Activity
of Doubly Modified Salinomycin
Analogs&#8211;Evaluation in Vitro and Ex Vivo</article-title><source>Eur. J. Med. Chem.</source><year>2018</year><volume>156</volume><fpage>510</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2018.07.021</pub-id><pub-id pub-id-type="pmid">30025346</pub-id></element-citation></ref><ref id="ref36"><element-citation publication-type="journal" id="cit36"><name name-style="western"><surname>Hodo&#328;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Frydrych</surname><given-names>I.</given-names></name><name name-style="western"><surname>Trhl&#237;kov&#225;</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pokorn&#253;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Borkov&#225;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Benick&#225;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vlk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li&#353;kov&#225;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kub&#237;&#269;kov&#225;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Medved&#237;kov&#225;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pis&#225;r</surname><given-names>M.</given-names></name><name name-style="western"><surname>&#352;arek</surname><given-names>J.</given-names></name><name name-style="western"><surname>Das</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ligasov&#225;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koberna</surname><given-names>K.</given-names></name><name name-style="western"><surname>D&#382;ub&#225;k</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hajd&#250;ch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Urban</surname><given-names>M.</given-names></name><article-title>Triterpenoid Pyrazines and Pyridines&#8211;Synthesis, Cytotoxicity,
Mechanism of Action, Preparation of Prodrugs</article-title><source>Eur. J. Med. Chem.</source><year>2022</year><volume>243</volume><elocation-id>114777</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejmech.2022.114777</pub-id><pub-id pub-id-type="pmid">36174412</pub-id></element-citation></ref><ref id="ref37"><element-citation publication-type="journal" id="cit37"><name name-style="western"><surname>&#199;apc&#305;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lorion</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Leidenberger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Borges Silva</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>D. R. M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y. M.</given-names></name><name name-style="western"><surname>Friedrich</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kappes</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ackermann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tsogoeva</surname><given-names>S. B.</given-names></name><article-title>Artemisinin&#8211;(Iso)&#173;Quinoline Hybrids by C&#8211;H
Activation and Click Chemistry: Combating Multidrug-Resistant Malaria</article-title><source>Angew. Chem., Int. Ed.</source><year>2019</year><volume>58</volume><issue>37</issue><fpage>13066</fpage><lpage>13079</lpage><pub-id pub-id-type="doi">10.1002/anie.201907224</pub-id><pub-id pub-id-type="pmcid">PMC6899722</pub-id><pub-id pub-id-type="pmid">31290221</pub-id></element-citation></ref><ref id="ref38"><element-citation publication-type="journal" id="cit38"><name name-style="western"><surname>Hirumi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hirumi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Doyle</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Cross</surname><given-names>G. A. M.</given-names></name><article-title>In Vitro Cloning
of Animal-Infective Bloodstream Forms of Trypanosoma Brucei</article-title><source>Parasitology</source><year>1980</year><volume>80</volume><issue>2</issue><fpage>371</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1017/S0031182000000822</pub-id><pub-id pub-id-type="pmid">6154276</pub-id></element-citation></ref><ref id="ref39"><element-citation publication-type="journal" id="cit39"><name name-style="western"><surname>Collins</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>R. E.</given-names></name><article-title>Continuous
Growth and Differentiation
of Human Myeloid Leukaemic Cells in Suspension Culture</article-title><source>Nature</source><year>1977</year><volume>270</volume><issue>5635</issue><fpage>347</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1038/270347a0</pub-id><pub-id pub-id-type="pmid">271272</pub-id></element-citation></ref><ref id="ref40"><element-citation publication-type="journal" id="cit40"><name name-style="western"><surname>Baltz</surname><given-names>T.</given-names></name><name name-style="western"><surname>Baltz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Giroud</surname><given-names>C.</given-names></name><name name-style="western"><surname>Crockett</surname><given-names>J.</given-names></name><article-title>Cultivation in a Semi-Defined
Medium of Animal Infective Forms of Trypanosoma Brucei, T. Equiperdum,
T. Evansi, T. Rhodesiense and T. Gambiense</article-title><source>EMBO J.</source><year>1985</year><volume>4</volume><issue>5</issue><fpage>1273</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1985.tb03772.x</pub-id><pub-id pub-id-type="pmid">4006919</pub-id><pub-id pub-id-type="pmcid">PMC554336</pub-id></element-citation></ref><ref id="ref41"><element-citation publication-type="journal" id="cit41"><name name-style="western"><surname>Huber</surname><given-names>W.</given-names></name><name name-style="western"><surname>Koella</surname><given-names>J. C.</given-names></name><article-title>A Comparison of
Three Methods of Estimating EC<sub>50</sub> in Studies of Drug Resistance
of Malaria Parasites</article-title><source>Acta Trop.</source><year>1993</year><volume>55</volume><issue>4</issue><fpage>257</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/0001-706X(93)90083-N</pub-id><pub-id pub-id-type="pmid">8147282</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>